Allison J Mcgeer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/309799/publications.pdf

Version: 2024-02-01

4741 2832 39,176 566 97 175 citations h-index g-index papers 579 579 579 39194 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Secondary attack rates from asymptomatic and symptomatic influenza virus shedders in hospitals: Results from the TransFLUas influenza transmission study. Infection Control and Hospital Epidemiology, 2022, 43, 312-318.	1.0	9
2	Low yield of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) asymptomatic routine screen testing, despite high community incidence. Infection Control and Hospital Epidemiology, 2022, 43, 1527-1528.	1.0	2
3	Adverse Outcomes Associated With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant B.1.351 Infection in Vaccinated Residents of a Long-Term Care Home, Ontario, Canada. Clinical Infectious Diseases, 2022, 74, 751-752.	2.9	14
4	Coronavirus Disease 2019 (COVID-19) Outbreak Associated With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) P.1 Lineage in a Long-Term Care Home After Implementation of a Vaccination Program—Ontario, Canada, April–May 2021. Clinical Infectious Diseases, 2022, 74, 1085-1088.	2.9	27
5	Linear Regression Equations To Predict \hat{l}^2 -Lactam, Macrolide, Lincosamide, and Fluoroquinolone MICs from Molecular Antimicrobial Resistance Determinants in <i>Streptococcus pneumoniae</i> Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0137021.	1.4	9
6	Surface and Air Contamination With Severe Acute Respiratory Syndrome Coronavirus 2 From Hospitalized Coronavirus Disease 2019 Patients in Toronto, Canada, March–May 2020. Journal of Infectious Diseases, 2022, 225, 768-776.	1.9	20
7	The Canadian National Vaccine Safety Network: surveillance of adverse events following immunisation among individuals immunised with the COVID-19 vaccine, a cohort study in Canada. BMJ Open, 2022, 12, e051254.	0.8	9
8	High pressure processing inactivates human cytomegalovirus and hepatitis A virus while preserving macronutrients and native lactoferrin in human milk. Innovative Food Science and Emerging Technologies, 2022, 75, 102891.	2.7	9
9	Burden of severe illness associated with laboratory confirmed influenza in adults aged 50–64 years: A rapid review. Influenza and Other Respiratory Viruses, 2022, 16, 632-642.	1.5	3
10	Longitudinal Plasma Proteomics Analysis Reveals Novel Candidate Biomarkers in Acute COVID-19. Journal of Proteome Research, 2022, 21, 975-992.	1.8	27
11	Impact of respirator versus surgical masks on SARS-CoV-2 acquisition in healthcare workers: a prospective multicentre cohort. Antimicrobial Resistance and Infection Control, 2022, 11, 27.	1.5	20
12	Persistence of T Cell and Antibody Responses to SARS-CoV-2 Up to 9 Months after Symptom Onset. Journal of Immunology, 2022, 208, 429-443.	0.4	12
13	A scalable serology solution for profiling humoral immune responses to SARSâ€CoVâ€2 infection and vaccination. Clinical and Translational Immunology, 2022, 11, e1380.	1.7	65
14	Ultrasensitive assay for saliva-based SARS-CoV-2 antigen detection. Clinical Chemistry and Laboratory Medicine, 2022, 60, 771-777.	1.4	11
15	2% aqueous vs alcohol-based chlorhexidine for skin antisepsis in VLBW neonates undergoing peripheral venipuncture: a non-inferiority trial. Journal of Perinatology, 2022, 42, 636-641.	0.9	3
16	Study of the epidemiology of COVID-19 in Ontario elementary and secondary school education workers: an interim analysis following the first school year. Canadian Journal of Public Health, 2022, 113, 185-195.	1,1	2
17	eP325: Medically actionable DNA variation from the GENCOV COVID-19 Genome Sequencing Study. Genetics in Medicine, 2022, 24, S203-S204.	1.1	O
18	Antimicrobial use in Canadian acute-care hospitals: Findings from three national point-prevalence surveys between 2002 and 2017. Infection Control and Hospital Epidemiology, 2022, 43, 1558-1564.	1.0	2

#	Article	IF	Citations
19	Recalibrated estimates of non-bacteremic and bacteremic pneumococcal community acquired pneumonia in hospitalized Canadian adults from 2010 to 2017 with addition of an extended spectrum serotype-specific urine antigen detection assay. Vaccine, 2022, 40, 2635-2646.	1.7	6
20	Organ dysfunction and death in patients admitted to hospital with COVID-19 in pandemic waves 1 to 3 in British Columbia, Ontario and Quebec, Canada: a cohort study. CMAJ Open, 2022, 10, E379-E389.	1.1	3
21	Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants. Med, 2022, 3, 422-432.e3.	2.2	9
22	Severity of Omicron SARS-CoV-2 Infection in Vaccinated and Unvaccinated Residents of Long Term Care Homes. Infection Control and Hospital Epidemiology, 2022, , 1-5.	1.0	0
23	Older Age and Frailty are Associated with Higher Mortality but Lower ICU Admission with COVID-19. Canadian Geriatrics Journal, 2022, 25, 183-196.	0.7	2
24	Longitudinal Assessment of SARS-CoV-2-Specific T Cell Cytokine-Producing Responses for 1 Year Reveals Persistence of Multicytokine Proliferative Responses, with Greater Immunity Associated with Disease Severity. Journal of Virology, 2022, 96, .	1.5	19
25	Household Transmission of Carbapenemase-producing Enterobacterales in Ontario, Canada. Clinical Infectious Diseases, 2021, 73, e4607-e4615.	2.9	8
26	Association Between Hospital Outbreaks and Hand Hygiene: Insights from Electronic Monitoring. Clinical Infectious Diseases, 2021, 73, e3656-e3660.	2.9	9
27	Sensitivity of Nasopharyngeal Swabs and Saliva for the Detection of Severe Acute Respiratory Syndrome Coronavirus 2. Clinical Infectious Diseases, 2021, 72, 1064-1066.	2.9	171
28	Identification of prosthetic hip and knee joint infections using administrative databasesâ€"A validation study. Infection Control and Hospital Epidemiology, 2021, 42, 325-330.	1.0	7
29	Prevalence of SARS-CoV-2 antibodies among Swiss hospital workers: Results of a prospective cohort study. Infection Control and Hospital Epidemiology, 2021, 42, 604-608.	1.0	20
30	Systematic Examination of Antigen-Specific Recall T Cell Responses to SARS-CoV-2 versus Influenza Virus Reveals a Distinct Inflammatory Profile. Journal of Immunology, 2021, 206, 37-50.	0.4	28
31	Persistent Functional Decline Following Hospitalization with Influenza or Acute Respiratory Illness. Journal of the American Geriatrics Society, 2021, 69, 696-703.	1.3	34
32	Safety, effectiveness and sustainability of a laboratory intervention to de-adopt culture of midstream urine samples among hospitalized patients. Infection Control and Hospital Epidemiology, 2021, 42, 43-50.	1.0	1
33	Detection of SARS-CoV-2 Viral Particles Using Direct, Reagent-Free Electrochemical Sensing. Journal of the American Chemical Society, 2021, 143, 1722-1727.	6.6	156
34	Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2021, 325, 39.	3.8	65
35	Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update. Critical Care Medicine, 2021, 49, e219-e234.	0.4	289
36	Detection of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) in outpatients: A multicenter comparison of self-collected saline gargle, oral swab, and combined oral–anterior nasal swab to a provider collected nasopharyngeal swab. Infection Control and Hospital Epidemiology, 2021, 42, 1340-1344.	1.0	34

#	Article	IF	Citations
37	Standard versus combined chemical, mechanical, and heat decontamination of hospital drains harboring carbapenemase-producing organisms (CPOs): A randomized controlled trial. Infection Control and Hospital Epidemiology, 2021, 42, 1-4.	1.0	1
38	Rapid antigen screening of asymptomatic people as a public health tool to combat COVID-19. Cmaj, 2021, 193, E449-E452.	0.9	22
39	Changes in Invasive Pneumococcal Disease Caused by Streptococcus pneumoniae Serotype 1 following Introduction of PCV10 and PCV13: Findings from the PSERENADE Project. Microorganisms, 2021, 9, 696.	1.6	10
40	Post-exposure prophylaxis against SARS-CoV-2 in close contacts of confirmed COVID-19 cases (CORIPREV): study protocol for a cluster-randomized trial. Trials, 2021, 22, 224.	0.7	8
41	Serotype Distribution of Remaining Pneumococcal Meningitis in the Mature PCV10/13 Period: Findings from the PSERENADE Project. Microorganisms, 2021, 9, 738.	1.6	31
42	Hospital antibiotic prescribing patterns in adult patients according to the WHO Access, Watch and Reserve classification (AWaRe): results from a worldwide point prevalence survey in 69 countries. Journal of Antimicrobial Chemotherapy, 2021, 76, 1614-1624.	1.3	60
43	Global Landscape Review of Serotype-Specific Invasive Pneumococcal Disease Surveillance among Countries Using PCV10/13: The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) Project. Microorganisms, 2021, 9, 742.	1.6	30
44	Experimental and natural evidence of SARS-CoV-2-infection-induced activation of type I interferon responses. IScience, 2021, 24, 102477.	1.9	49
45	Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial. Trials, 2021, 22, 323.	0.7	21
46	Temporal Dynamics and Evolution of SARS-CoV-2 Demonstrate the Necessity of Ongoing Viral Genome Sequencing in Ontario, Canada. MSphere, 2021, 6, .	1.3	7
47	Surveilling and Tracking COVID-19 Patients Using a Portable Quantum Dot Smartphone Device. Nano Letters, 2021, 21, 5209-5216.	4.5	38
48	Genomic Epidemiology of Carbapenemase-Producing <i>Enterobacterales</i> at a Hospital System in Toronto, Ontario, Canada, 2007 to 2018. Antimicrobial Agents and Chemotherapy, 2021, 65, e0036021.	1.4	4
49	The impact of acute pneumococcal disease on health state utility values: a systematic review. Quality of Life Research, 2021, , 1.	1.5	4
50	Population Genomics of <i>emm4</i> Group A Streptococcus Reveals Progressive Replacement with a Hypervirulent Clone in North America. MSystems, 2021, 6, e0049521.	1.7	5
51	Revisiting the evidence for physical distancing, face masks, and eye protection. Lancet, The, 2021, 398, 663.	6.3	4
52	Implementation of serological and molecular tools to inform COVID-19 patient management: protocol for the GENCOV prospective cohort study. BMJ Open, 2021, 11, e052842.	0.8	6
53	Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine, 2021, 27, 2012-2024.	15.2	206
54	Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis. JAMA Network Open, 2021, 4, e2123622.	2.8	49

#	Article	IF	CITATIONS
55	Non-occupational and occupational factors associated with specific SARS-CoV-2 antibodies among hospital workers $\hat{a} \in A$ multicentre cross-sectional study. Clinical Microbiology and Infection, 2021, 27, 1336-1344.	2.8	32
56	Key policy and programmatic factors to improve influenza vaccination rates based on the experience from four high-performing countries. Drugs in Context, 2021, 9, 1-13.	1.0	11
57	Sensitivity of midturbinate versus nasopharyngeal swabs for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Infection Control and Hospital Epidemiology, 2021, 42, 1001-1003.	1.0	19
58	Absenteeism and presenteeism in healthcare workers due to respiratory illness. Infection Control and Hospital Epidemiology, 2021, 42, 268-273.	1.0	14
59	SARS-CoV-2 antibodies in Ontario health care workers during and after the first wave of the pandemic: a cohort study. CMAJ Open, 2021, 9, E929-E939.	1.1	10
60	Influenza Vaccine Effectiveness Against All-Cause Mortality Following Laboratory-Confirmed Influenza in Older Adults, 2010–2011 to 2015–2016 Seasons in Ontario, Canada. Clinical Infectious Diseases, 2021, 73, e1191-e1199.	2.9	9
61	Are Sink Drainage Systems a Reservoir for Hospital-Acquired Gammaproteobacteria Colonization and Infection? A Systematic Review. Open Forum Infectious Diseases, 2021, 8, ofaa590.	0.4	19
62	Infectious Diseases Society of America Guidelines on Infection Prevention for Healthcare Personnel Caring for Patients With Suspected or Known Coronavirus Disease 2019. Clinical Infectious Diseases, 2021, , .	2.9	16
63	Population-based incidence of invasive pneumococcal disease in children and adults in Ontario and British Columbia, 2002–2018: A Canadian Immunization Research Network (CIRN) study. Vaccine, 2021, 39, 7545-7553.	1.7	5
64	The 2018 Global Point Prevalence Survey of antimicrobial consumption and resistance in 47 Canadian hospitals: a cross-sectional survey. CMAJ Open, 2021, 9, E1242-E1251.	1.1	8
65	Dried blood spot specimens for SARS-CoV-2 antibody testing: A multi-site, multi-assay comparison. PLoS ONE, 2021, 16, e0261003.	1.1	24
66	Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection. Journal of Infectious Diseases, 2020, 221, 356-366.	1.9	17
67	The Urine-culturing Cascade: Variation in Nursing Home Urine Culturing and Association With Antibiotic Use and Clostridiodes difficile Infection. Clinical Infectious Diseases, 2020, 70, 1620-1627.	2.9	15
68	Influenza Vaccine Effectiveness in Preventing Hospitalizations in Older Patients With Chronic Obstructive Pulmonary Disease. Journal of Infectious Diseases, 2020, 221, 42-52.	1.9	7
69	Are healthcare personnel at higher risk of seasonal influenza than other working adults?. Infection Control and Hospital Epidemiology, 2020, 41, 267-272.	1.0	1
70	A suspected septic transfusion reaction associated with posttransfusion contamination of a platelet pool by vancomycinâ€resistant <scp><i>Enterococcus faecium</i></scp> . Transfusion, 2020, 60, 430-435.	0.8	3
71	Influenza Vaccination to Reduce Cardiovascular Morbidity and Mortality in Patients With COVID-19. Journal of the American College of Cardiology, 2020, 76, 1777-1794.	1.2	57
72	Finding the Right Balance: An Evidence-Informed Guidance Document to Support the Re-Opening of Canadian Nursing Homes to Family Caregivers and Visitors during the Coronavirus Disease 2019 Pandemic. Journal of the American Medical Directors Association, 2020, 21, 1365-1370.e7.	1.2	56

#	Article	IF	Citations
73	Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Science Immunology, 2020, 5, .	5.6	714
74	The 2017 global point prevalence survey of antimicrobial consumption and resistance in Canadian hospitals. Antimicrobial Resistance and Infection Control, 2020, 9, 104.	1.5	12
75	Infectious Diseases Society of America Guidelines on Infection Prevention for Healthcare Personnel Caring for Patients With Suspected or Known Coronavirus Disease 2019. Clinical Infectious Diseases, 2020, , .	2.9	75
76	Isolation, Sequence, Infectivity, and Replication Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2. Emerging Infectious Diseases, 2020, 26, 2054-2063.	2.0	118
77	Dissemination of Verona Integron-encoded Metallo- \hat{l}^2 -lactamase among clinical and environmental Enterobacteriaceae isolates in Ontario, Canada. Scientific Reports, 2020, 10, 18580.	1.6	12
78	Low incidence of airborne SARS-CoV-2 in acute care hospital rooms with optimized ventilation. Emerging Microbes and Infections, 2020, 9, 2597-2605.	3.0	39
79	Association of Influenza Activity and Environmental Conditions With the Risk of Invasive Pneumococcal Disease. JAMA Network Open, 2020, 3, e2010167.	2.8	11
80	Genomic Epidemiology of Invasive Methicillin-Resistant <i>Staphylococcus aureus</i> Infections Among Hospitalized Individuals in Ontario, Canada. Journal of Infectious Diseases, 2020, 222, 2071-2081.	1.9	8
81	The starting line for COVID-19 vaccine development. Lancet, The, 2020, 395, 1815-1816.	6.3	19
82	Prevalence of Candida auris in Canadian acute care hospitals among at-risk patients, 2018. Antimicrobial Resistance and Infection Control, 2020, 9, 82.	1.5	7
83	Age-stratified burden of pneumococcal community acquired pneumonia in hospitalised Canadian adults from 2010 to 2015. BMJ Open Respiratory Research, 2020, 7, e000550.	1.2	21
84	Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Medicine, 2020, 46, 854-887.	3.9	1,536
85	The Clinical Burden of Clostridioides difficile in Ontario, Canada. Open Forum Infectious Diseases, 2020, 7, ofz523.	0.4	1
86	Frequency of hand hygiene opportunities in patients on a general surgery service. American Journal of Infection Control, 2020, 48, 490-495.	1.1	5
87	Antimicrobial use among adult inpatients at hospital sites within the Canadian Nosocomial Infection Surveillance Program: 2009 to 2016. Antimicrobial Resistance and Infection Control, 2020, 9, 32.	1.5	12
88	Preparedness for Candida auris in Canadian Nosocomial Infection Surveillance Program (CNISP) hospitals, 2018. Infection Control and Hospital Epidemiology, 2020, 41, 361-364.	1.0	1
89	Introduction of Group Electronic Monitoring of Hand Hygiene on Inpatient Units: A Multicenter Cluster Randomized Quality Improvement Study. Clinical Infectious Diseases, 2020, 71, e680-e685.	2.9	21
90	Frailty Hinders Recovery From Influenza and Acute Respiratory Illness in Older Adults. Journal of Infectious Diseases, 2020, 222, 428-437.	1.9	34

#	Article	IF	CITATIONS
91	Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19). Critical Care Medicine, 2020, 48, e440-e469.	0.4	816
92	A simple protein-based surrogate neutralization assay for SARS-CoV-2. JCI Insight, 2020, 5, .	2.3	193
93	The impact of repeated vaccination using 10-year vaccination history on protection against influenza in older adults: a test-negative design study across the $2010/11$ to $2015/16$ influenza seasons in Ontario, Canada. Eurosurveillance, $2020, 25, .$	3.9	15
94	Incidence and economic burden of <i>Clostridioides difficile</i> infection in Ontario: a retrospective population-based study. CMAJ Open, 2020, 8, E16-E25.	1.1	14
95	Chemical, Mechanical, and Heat Cleaning to Decontaminate Hospital Drains Harboring Carbapenemase-Producing Enterobacteriales. Infection Control and Hospital Epidemiology, 2020, 41, s466-s467.	1.0	0
96	Central-line–Associated Bloodstream Infections Among Adult Intensive Care Unit Patients in Canadian Hospitals, 2011–2018. Infection Control and Hospital Epidemiology, 2020, 41, s464-s465.	1.0	0
97	National Surveillance of Methicillin-Resistant <i>Staphylococcus aureus</i> Bloodstream Infections in Canadian Acute-Care Hospitals. Infection Control and Hospital Epidemiology, 2020, 41, s72-s73.	1.0	0
98	Variability in Antimicrobial Use Among Hospitals Participating in the Canadian Nosocomial Infection Surveillance Program. Infection Control and Hospital Epidemiology, 2020, 41, s509-s509.	1.0	O
99	Immunogenicity and reactogenicity of high- vs. standard-dose trivalent inactivated influenza vaccine in healthcare workers: a pilot randomized controlled trial. Clinical Microbiology and Infection, 2019, 25, 217-224.	2.8	3
100	Can routinely collected laboratory and health administrative data be used to assess influenza vaccine effectiveness? Assessing the validity of the Flu and Other Respiratory Viruses Research (FOREVER) Cohort. Vaccine, 2019, 37, 4392-4400.	1.7	28
101	Streptococcus pneumoniae serotype 3 is masking PCV13-mediated herd immunity in Canadian adults hospitalized with community acquired pneumonia: A study from the Serious Outcomes Surveillance (SOS) Network of the Canadian immunization research Network (CIRN). Vaccine, 2019, 37, 5466-5473.	1.7	29
102	Exploring indirect protection associated with influenza immunization – A systematic review of the literature. Vaccine, 2019, 37, 7213-7232.	1.7	6
103	Effectiveness of Influenza Vaccination on Hospitalizations and Risk Factors for Severe Outcomes in Hospitalized Patients With COPD. Chest, 2019, 155, 69-78.	0.4	67
104	Influenza Vaccine Effectiveness Among Patients With Cancer: A Population-Based Study Using Health Administrative and Laboratory Testing Data From Ontario, Canada. Journal of Clinical Oncology, 2019, 37, 2795-2804.	0.8	41
105	The TransFLUas influenza transmission study in acute healthcare - recruitment rates and protocol adherence in healthcare workers and inpatients. BMC Infectious Diseases, 2019, 19, 446.	1.3	6
106	Which healthcare workers work with acute respiratory illness? Evidence from Canadian acute-care hospitals during 4 influenza seasons: 2010–2011 to 2013–2014. Infection Control and Hospital Epidemiology, 2019, 40, 889-896.	1.0	24
107	Infection prevention and control practices related to carbapenemase-producing <i>Enterobacteriaceae</i> (CPE) in acute-care hospitals in Ontario, Canada. Infection Control and Hospital Epidemiology, 2019, 40, 1006-1012.	1.0	17
108	Influenza virus RNA recovered from droplets and droplet nuclei emitted by adults in an acute care setting. Journal of Occupational and Environmental Hygiene, 2019, 16, 341-348.	0.4	19

#	Article	IF	CITATIONS
109	Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. Clinical Infectious Diseases, 2019, 68, 895-902.	2.9	251
110	Multilocus Variable-Number Tandem-Repeat Analysis of Clostridioides difficile Clusters in Ribotype 027 Isolates and Lack of Association with Clinical Outcomes. Journal of Clinical Microbiology, 2019, 57, .	1.8	3
111	Evidence of transmission of Clostridium difficile in asymptomatic patients following admission screening in a tertiary care hospital. PLoS ONE, 2019, 14, e0207138.	1.1	13
112	Trends in health care–associated infections in acute care hospitals in Canada: an analysis of repeated point-prevalence surveys. Cmaj, 2019, 191, E981-E988.	0.9	29
113	Predictors of Treatment Failure for Hip and Knee Prosthetic Joint Infections in the Setting of 1- and 2-Stage Exchange Arthroplasty: A Multicenter Retrospective Cohort. Open Forum Infectious Diseases, 2019, 6, ofz452.	0.4	43
114	Characteristics and Outcomes of Young Children Hospitalized With Laboratory-confirmed Influenza or Respiratory Syncytial Virus in Ontario, Canada, 2009–2014. Pediatric Infectious Disease Journal, 2019, 38, 362-369.	1.1	11
115	External validation of clinical prediction rules for complications and mortality following Clostridioides difficile infection. PLoS ONE, 2019, 14, e0226672.	1.1	9
116	Interfacility patient sharing and Clostridioides difficile infection incidence in the Ontario hospital system: A 13-year cohort study. Infection Control and Hospital Epidemiology, 2019, 41, 1-7.	1.0	0
117	Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. Clinical Infectious Diseases, 2019, 68, e1-e47.	2.9	449
118	Prevalence of antibiotic-resistant organisms in Canadian Hospitals. Comparison of point-prevalence survey results from 2010, 2012, and 2016. Infection Control and Hospital Epidemiology, 2019, 40, 53-59.	1.0	12
119	Results from the Canadian Nosocomial Infection Surveillance Program for detection of carbapenemase-producing∢i>Acinetobacter∢li>spp. in Canadian hospitals, 2010–16. Journal of Antimicrobial Chemotherapy, 2019, 74, 315-320.	1.3	16
120	The Impact of Prior Season Vaccination on Subsequent Influenza Vaccine Effectiveness to Prevent Influenza-related Hospitalizations Over 4 Influenza Seasons in Canada. Clinical Infectious Diseases, 2019, 69, 970-979.	2.9	18
121	Stability of Inactivated Influenza Vaccine in Polypropylene Syringes under Various Storage Conditions. Canadian Journal of Hospital Pharmacy, 2019, 72, 462-463.	0.1	0
122	Factors associated with influenza vaccination among healthcare workers in acute care hospitals in Canada. Influenza and Other Respiratory Viruses, 2018, 12, 319-325.	1.5	16
123	Factors Associated With 30-Day Mortality Rate in Respiratory Infections Caused by Streptococcus pneumoniae. Clinical Infectious Diseases, 2018, 66, 1282-1285.	2.9	2
124	Resistance patterns of Enterobacteriaceae in urines are similar in symptomatic and asymptomatic patients. Journal of Hospital Infection, 2018, 99, 419-421.	1.4	0
125	Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. New England Journal of Medicine, 2018, 378, 345-353.	13.9	821
126	Impact of Neonatal Intensive Care Unit Admission on Bacterial Colonization of Donated Human Milk. Journal of Human Lactation, 2018, 34, 350-354.	0.8	6

#	Article	IF	Citations
127	Influenza vaccine effectiveness to prevent influenza-related hospitalizations and serious outcomes in Canadian adults over the 2011/12 through 2013/14 influenza seasons: A pooled analysis from the Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS Network). Vaccine, 2018, 36, 2166-2175.	1.7	52
128	Impact of Pneumococcal Vaccination on Pneumonia Hospitalizations and Related Costs in Ontario: A Population-Based Ecological Study. Clinical Infectious Diseases, 2018, 66, 541-547.	2.9	27
129	Resource utilization and cost of influenza requiring hospitalization in Canadian adults: A study from the serious outcomes surveillance network of the Canadian Immunization Research Network. Influenza and Other Respiratory Viruses, 2018, 12, 232-240.	1.5	28
130	Influenza vaccine effectiveness among cancer patients: A population-based study using health administrative and laboratory testing data from Ontario, Canada. Annals of Oncology, 2018, 29, viii568.	0.6	1
131	308. Identification of Prosthetic Hip and Knee Joint Infections in Administrative Databases. Open Forum Infectious Diseases, 2018, 5, S125-S125.	0.4	O
132	2401. Risk Factors for Antimicrobial Resistance in Invasive Pneumococcal disease (IPD) in Toronto, Canada, 2012–2017. Open Forum Infectious Diseases, 2018, 5, S717-S717.	0.4	0
133	2166. Preparedness for <i>Candida auris</i> in Canadian Nosocomial Infection Surveillance Program (CNISP) Hospitals, 2018. Open Forum Infectious Diseases, 2018, 5, S639-S639.	0.4	0
134	Emerging antimicrobial resistance among <i>Escherichia coli</i> strains in bloodstream infections in Toronto, 2006–2016: a retrospective cohort study. CMAJ Open, 2018, 6, E580-E586.	1.1	12
135	Hand hygiene opportunities on Canadian acute-care inpatient units: A multicenter observational study. Infection Control and Hospital Epidemiology, 2018, 39, 1378-1380.	1.0	6
136	Exposure to rabies during pregnancy. Cmaj, 2018, 190, E1281-E1283.	0.9	0
137	Genetic Diversity and Antimicrobial Drug Resistance of Serotype VI Group B Streptococcus, Canada. Emerging Infectious Diseases, 2018, 24, 1941-1942.	2.0	2
138	Comparison of qPCR versus culture for the detection and quantification of Clostridium difficile environmental contamination. PLoS ONE, 2018, 13, e0201569.	1.1	7
139	High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial. American Heart Journal, 2018, 202, 97-103.	1.2	38
140	Canada-Wide Epidemic of emm74 Group A Streptococcus Invasive Disease. Open Forum Infectious Diseases, 2018, 5, ofy085.	0.4	15
141	Serotype distribution of invasive Streptococcus pneumoniae in adults 65†years of age and over after the introduction of childhood 13-valent pneumococcal conjugate vaccination programs in Canada, 2010†2016. Vaccine, 2018, 36, 4701-4707.	1.7	23
142	Comparison of response rates on invitation mode of a web-based survey on influenza vaccine adverse events among healthcare workers: a pilot study. BMC Medical Research Methodology, 2018, 18, 59.	1.4	13
143	Use of Genome Sequencing to Define Institutional Influenza Outbreaks, Toronto, Ontario, Canada, 2014–15. Emerging Infectious Diseases, 2018, 24, 492-497.	2.0	22
144	Contact among healthcare workers in the hospital setting: developing the evidence base for innovative approaches to infection control. BMC Infectious Diseases, 2018, 18, 184.	1.3	18

#	Article	IF	CITATIONS
145	Increased environmental sample area and recovery ofClostridium difficilespores from hospital surfaces by quantitative PCR and enrichment culture. Infection Control and Hospital Epidemiology, 2018, 39, 917-923.	1.0	8
146	Emergence of Carbapenemase-Producing <i>Enterobacteriaceae</i> , South-Central Ontario, Canada 1. Emerging Infectious Diseases, 2018, 24, 1674-1682.	2.0	25
147	Patient- and hospital-level predictors of vancomycin-resistant Enterococcus (VRE) bacteremia in Ontario, Canada. American Journal of Infection Control, 2018, 46, 1266-1271.	1.1	23
148	Nasal colonization with Streptococcus pneumoniae and Staphylococcus aureus among hospitalized patients with laboratory-confirmed influenza. Diagnostic Microbiology and Infectious Disease, 2018, 92, 133-135.	0.8	0
149	Prevalence of vancomycin-variable Enterococcus faecium (VVE) among vanA-positive sterile site isolates and patient factors associated with VVE bacteremia. PLoS ONE, 2018, 13, e0193926.	1.1	29
150	Pre-and post-pandemic trends in antiviral use in hospitalized patients with laboratory-confirmed influenza: 2004/05–2013/14, Toronto, Canada. Antiviral Research, 2017, 140, 158-163.	1.9	6
151	Active Surveillance for Influenza Reduces but Does Not Eliminate Hospital Exposure to Patients With Influenza. Infection Control and Hospital Epidemiology, 2017, 38, 387-392.	1.0	6
152	Burden of vaccine-preventable pneumococcal disease in hospitalized adults: A Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS) network study. Vaccine, 2017, 35, 3647-3654.	1.7	26
153	Detecting and quantifying influenza virus with self†versus investigatorâ€collected midâ€turbinate nasal swabs. Journal of Medical Virology, 2017, 89, 1295-1299.	2.5	7
154	Unit-Specific Rates of Hand Hygiene Opportunities in an Acute-Care Hospital. Infection Control and Hospital Epidemiology, 2017, 38, 411-416.	1.0	7
155	Carbapenem Resistance, Initial Antibiotic Therapy, and Mortality in <i>Klebsiella pneumoniae</i> Bacteremia: A Systematic Review and Meta-Analysis. Infection Control and Hospital Epidemiology, 2017, 38, 1319-1328.	1.0	88
156	The Effect of Hospital Isolation Precautions on Patient Outcomes and Cost of Care: A Multi-Site, Retrospective, Propensity Score-Matched Cohort Study. Journal of General Internal Medicine, 2017, 32, 262-268.	1.3	63
157	Serotype Distribution, Population Structure, and Antimicrobial Resistance of Group B Streptococcus Strains Recovered from Colonized Pregnant Women. Journal of Clinical Microbiology, 2017, 55, 412-422.	1.8	80
158	Optimal hand washing technique to minimize bacterial contamination before neuraxial anesthesia: a randomized control trial. International Journal of Obstetric Anesthesia, 2017, 29, 39-44.	0.2	6
159	Influenza and rhinovirus viral load and disease severity in upper respiratory tract infections. Journal of Clinical Virology, 2017, 86, 14-19.	1.6	80
160	Oral Vancomycin Followed by Fecal Transplantation Versus Tapering Oral Vancomycin Treatment for Recurrent Clostridium difficile Infection: An Open-Label, Randomized Controlled Trial. Clinical Infectious Diseases, 2017, 64, 265-271.	2.9	145
161	Community- and Healthcare-Associated Methicillin-Resistant Staphylococcus aureus Strains: An Investigation Into Household Transmission, Risk Factors, and Environmental Contamination. Infection Control and Hospital Epidemiology, 2017, 38, 61-67.	1.0	14
162	Case–control study of household contacts to examine immunological protection from <i>Bordetella pertussis</i> transmission — study protocol. CMAJ Open, 2017, 5, E872-E877.	1.1	1

#	Article	IF	Citations
163	The Importance of Frailty in the Assessment of Influenza Vaccine Effectiveness Against Influenza-Related Hospitalization in Elderly People. Journal of Infectious Diseases, 2017, 216, 405-414.	1.9	133
164	Burden of Hospitalization Associated with Seasonal Influenza in Toronto, Canada, 2011–2016. Open Forum Infectious Diseases, 2017, 4, S315-S315.	0.4	0
165	Phylogenetic analysis of emergent Streptococcus pneumoniae serotype 22F causing invasive pneumococcal disease using whole genome sequencing. PLoS ONE, 2017, 12, e0178040.	1.1	21
166	Vaccine effectiveness against laboratory-confirmed influenza hospitalizations among young children during the 2010-11 to 2013-14 influenza seasons in Ontario, Canada. PLoS ONE, 2017, 12, e0187834.	1.1	27
167	Influenza vaccine effectiveness against influenza-related hospitalization during a season with mixed outbreaks of four influenza viruses: a test-negative case-control study in adults in Canada. BMC Infectious Diseases, 2017, 17, 805.	1.3	21
168	High Incidence of Invasive Group A Streptococcal Infections in Remote Indigenous Communities in Northwestern Ontario, Canada. Open Forum Infectious Diseases, 2017, 4, ofw243.	0.4	40
169	Rapid Emergence of a New Clone Impacts the Population at Risk and Increases the Incidence of Type emm89 Group A Streptococcus Invasive Disease. Open Forum Infectious Diseases, 2017, 4, ofx042.	0.4	4
170	Carbapenemase Gene Transfer among Canadian Patients Colonized or Infected with Carbapenemase-Producing Enterobacteriaceae. Open Forum Infectious Diseases, 2017, 4, S138-S138.	0.4	0
171	Measuring influenza RNA quantity after prolonged storage or multiple freeze/thaw cycles. Journal of Virological Methods, 2017, 247, 45-50.	1.0	16
172	Genetic evidence for a novel variant of the pilus island 1 backbone protein in group B Streptococcus. Journal of Medical Microbiology, 2017, 66, 1409-1415.	0.7	5
173	Invasive Pneumococcal Disease (IPD) in Children and Adults Following Introduction of Pneumococcal Conjugate Vaccines: Data From Population Based Surveillance 2001–2015. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
174	Clonal Complex 17 Group B Streptococcus strains causing invasive disease in neonates and adults originate from the same genetic pool. Scientific Reports, 2016, 6, 20047.	1.6	40
175	Recurrence of Clostridium difficile Infection in Patients with Inflammatory Bowel Disease: The RECIDIVISM Study. American Journal of Gastroenterology, 2016, 111, 1141-1146.	0.2	104
176	Epidemiological features of influenza in Canadian adult intensive care unit patients. Epidemiology and Infection, 2016, 144, 741-750.	1.0	24
177	Determinants of Outcome in Hospitalized Patients With Methicillin-Resistant <i>Staphylococcus aureus</i> Bloodstream Infection: Results From National Surveillance in Canada, 2008-2012. Infection Control and Hospital Epidemiology, 2016, 37, 390-397.	1.0	24
178	Acquisition of bacteria on health care workers' hands after contact with patient privacy curtains. American Journal of Infection Control, 2016, 44, 1385-1386.	1.1	16
179	Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09â€related pneumonia: an individual participant data metaâ€analysis. Influenza and Other Respiratory Viruses, 2016, 10, 192-204.	1.5	54
180	Characterization of Clinical Methicillin-Resistant Staphylococcus aureus (MRSA) Isolates From Canadian Hospitals, 2010–2015. Open Forum Infectious Diseases, 2016, 3, .	0.4	1

#	Article	IF	CITATIONS
181	Predictors of influenza among older adults in the emergency department. BMC Infectious Diseases, 2016, 16, 615.	1.3	41
182	High Incidence of Invasive Group A Streptococcus Disease Caused by Strains of Uncommon <i>emm</i> Types in Thunder Bay, Ontario, Canada. Journal of Clinical Microbiology, 2016, 54, 83-92.	1.8	55
183	Association of serotype with respiratory presentations of pneumococcal infection, Ontario, Canada, 2003–2011. Vaccine, 2016, 34, 846-853.	1.7	12
184	What Is the Appropriate Meropenem MIC for Screening of Carbapenemase-Producing Enterobacteriaceae in Low-Prevalence Settings?. Antimicrobial Agents and Chemotherapy, 2016, 60, 1556-1559.	1.4	52
185	Antimicrobial surfaces to prevent healthcare-associated infections: a systematic review. Journal of Hospital Infection, 2016, 92, 7-13.	1.4	116
186	Invasive Pneumococcal Disease Among Immunocompromised Persons: Implications for Vaccination Programs. Clinical Infectious Diseases, 2016, 62, 139-147.	2.9	97
187	Capsular Switching and Other Large-Scale Recombination Events in Invasive Sequence Type 1 Group B <i>Streptococcus</i> . Emerging Infectious Diseases, 2016, 22, 1941-1944.	2.0	22
188	Differences in efficiency, satisfaction and adverse events between self-administered intradermal and nurse-administered intramuscular influenza vaccines in hospital workers. Vaccine, 2015, 33, 6635-6640.	1.7	13
189	Simulation Study of the Effect of Influenza and Influenza Vaccination on Risk of Acquiring Guillain-Barré Syndrome. Emerging Infectious Diseases, 2015, 21, 224-231.	2.0	11
190	Examining Perceptions about Mandatory Influenza Vaccination of Healthcare Workers through Online Comments on News Stories. PLoS ONE, 2015, 10, e0129993.	1.1	15
191	Corticosteroid Therapy in Critical Illness due to Seasonal and Pandemic Influenza. Canadian Respiratory Journal, 2015, 22, 271-274.	0.8	2
192	Acceptance of intradermal inactivated influenza vaccines among hospital staff following 2 seasonal vaccination campaigns. Human Vaccines and Immunotherapeutics, 2015, 11, 2827-2830.	1.4	2
193	A Downward Trend of the Ratio of Influenza RNA Copy Number to Infectious Viral Titer in Hospitalized Influenza A-Infected Patients. Open Forum Infectious Diseases, 2015, 2, ofv166.	0.4	8
194	Randomized evaluation of live attenuated vs. inactivated influenza vaccines in schools (RELATIVES) pilot study: A cluster randomized trial. Vaccine, 2015, 33, 535-541.	1.7	13
195	Is the prevalence of antibiotic-resistant organisms changing in Canadian hospitals? Comparison of point-prevalence survey results in 2010 and 2012. Clinical Microbiology and Infection, 2015, 21, 553-559.	2.8	12
196	Zanamivir versus trivalent split virus influenza vaccine: a pilot randomized trial. Influenza and Other Respiratory Viruses, 2015, 9, 78-84.	1.5	1
197	Middle East respiratory syndrome. Cmaj, 2015, 187, 679-679.	0.9	0
198	Sequence type 1 group B <i>Streptococcus</i>), an emerging cause of invasive disease in adults, evolves by small genetic changes. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 6431-6436.	3.3	81

#	Article	IF	CITATIONS
199	Infectious Complications Following Transrectal Ultrasound-guided Prostate Biopsy: A Canadian Tertiary Cancer Center Experience. Infection Control and Hospital Epidemiology, 2015, 36, 614-616.	1.0	2
200	Protecting the Frontline: Designing an Infection Prevention Platform for Preventing Emerging Respiratory Viral Illnesses in Healthcare Personnel. Infection Control and Hospital Epidemiology, 2015, 36, 336-345.	1.0	11
201	Vancomycin-Variable Enterococcal Bacteremia. Journal of Clinical Microbiology, 2015, 53, 3951-3953.	1.8	6
202	Factors Associated With Complications of <i>Clostridium difficile </i> Prospective Cohort. Clinical Infectious Diseases, 2015, 61, 1781-1788.	2.9	46
203	Emergence of Serotype IV Group B Streptococcus Adult Invasive Disease in Manitoba and Saskatchewan, Canada, Is Driven by Clonal Sequence Type 459 Strains. Journal of Clinical Microbiology, 2015, 53, 2919-2926.	1.8	37
204	Vancomycin-Variable Enterococci Can Give Rise to Constitutive Resistance during Antibiotic Therapy. Antimicrobial Agents and Chemotherapy, 2015, 59, 1405-1410.	1.4	45
205	Interim estimates of 2014/15 influenza vaccine effectiveness in preventing laboratory-confirmed influenza-related hospitalisation from the Serious Outcomes Surveillance Network of the Canadian Immunization Research Network, January 2015. Eurosurveillance, 2015, 20, 21024.	3.9	48
206	Population Structure and Antimicrobial Resistance of Invasive Serotype IV Group B <i>Streptococcus</i> , Toronto, Ontario, Canada. Emerging Infectious Diseases, 2015, 21, 585-591.	2.0	39
207	Proteomic Analysis of a NAP1 Clostridium difficile Clinical Isolate Resistant to Metronidazole. PLoS ONE, 2014, 9, e82622.	1.1	72
208	125Single Nucleotide Polymorphisms Drive Phenotypic Diversity Among Sequence Type 1 Group B Streptococcus, An Emerging Cause of Invasive Disease in Adult Humans. Open Forum Infectious Diseases, 2014, 1, S12-S12.	0.4	0
209	798Hospitalization due to Respiratory Syncytial Virus (RSV) and Influenza Infection in Adult Patients: a Retrospective Cohort Study. Open Forum Infectious Diseases, 2014, 1, S227-S227.	0.4	0
210	Evolutionary pathway to increased virulence and epidemic group A <i>Streptococcus</i> disease derived from 3,615 genome sequences. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E1768-76.	3.3	215
211	In Vitro Activity of New Cephalosporins vs Streptococcus pneumoniae from the Canadian Bacterial Surveillance Network: 2008–2011. Current Microbiology, 2014, 69, 763-767.	1.0	3
212	Peripartum outcomes: non-adjuvanted v. adjuvanted H1N1 vaccination. Cmaj, 2014, 186, 137.1-137.	0.9	3
213	Reply to Vanhems et al. Infection Control and Hospital Epidemiology, 2014, 35, 1075-1075.	1.0	1
214	Respiratory syncytial virus infection-associated hospitalization in adults: a retrospective cohort study. BMC Infectious Diseases, 2014, 14, 665.	1.3	73
215	Reply to Chironda et al. Clinical Infectious Diseases, 2014, 59, 1039-1040.	2.9	0
216	The Effect of Gowning on Labor Epidural Catheter Colonization Rate. Regional Anesthesia and Pain Medicine, 2014, 39, 520-524.	1.1	11

#	Article	IF	Citations
217	Influenza vaccination and Guillain-Barré syndrome. Lancet Infectious Diseases, The, 2014, 14, 369-370.	4.6	1
218	Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respiratory Medicine, the, 2014, 2, 395-404.	5.2	527
219	Trends in antiviral therapy of adults hospitalized with influenza in Canada since the end of the 2009 pandemic. Antimicrobial Resistance and Infection Control, 2014, 3, 2.	1.5	9
220	A Systematic and Functional Classification of Streptococcus pyogenes That Serves as a New Tool for Molecular Typing and Vaccine Development. Journal of Infectious Diseases, 2014, 210, 1325-1338.	1.9	257
221	Characterization of Invasive Group B Streptococcus Strains from the Greater Toronto Area, Canada. Journal of Clinical Microbiology, 2014, 52, 1441-1447.	1.8	74
222	Previous Antibiotic Exposure and Antimicrobial Resistance in Invasive Pneumococcal Disease: Results From Prospective Surveillance. Clinical Infectious Diseases, 2014, 59, 944-952.	2.9	51
223	Health care workers, mandatory influenza vaccination policies and the law. Cmaj, 2014, 186, 1076-1080.	0.9	22
224	Complete sequences of a novel blaNDM-1-harbouring plasmid from Providencia rettgeri and an FII-type plasmid from Klebsiella pneumoniae identified in Canada. Journal of Antimicrobial Chemotherapy, 2014, 69, 637-642.	1.3	42
225	Outbreak of Vancomycin-Susceptible Enterococcus faecium Containing the Wild-Type <i>vanA</i> Gene. Journal of Clinical Microbiology, 2014, 52, 1682-1686.	1.8	47
226	Vancomycin-Variable Enterococcus faecium: <i>In Vivo</i> Emergence of Vancomycin Resistance in a Vancomycin-Susceptible Isolate. Journal of Clinical Microbiology, 2014, 52, 1766-1767.	1.8	27
227	Reducing Antimicrobial Therapy for Asymptomatic Bacteriuria Among Noncatheterized Inpatients: A Proof-of-Concept Study. Clinical Infectious Diseases, 2014, 58, 980-983.	2.9	131
228	Healthcare-Associated Influenza in Canadian Hospitals from 2006 to 2012. Infection Control and Hospital Epidemiology, 2014, 35, 169-175.	1.0	65
229	Rate of Healthcare Worker–Patient Interaction and Hand Hygiene Opportunities in an Acute Care Setting. Infection Control and Hospital Epidemiology, 2014, 35, 225-230.	1.0	10
230	External cues to action and influenza vaccination among post-graduate trainee physicians in Toronto, Canada. Vaccine, 2014, 32, 3830-3834.	1.7	13
231	The integration of barcode scanning technology into Canadian public health immunization settings. Vaccine, 2014, 32, 2748-2755.	1.7	21
232	Medusa's Ugly Head Again: From SARS to MERS-CoV. Annals of Internal Medicine, 2014, 160, 432-433.	2.0	3
233	Contamination of Canadian private drinking water sources with antimicrobial resistant Escherichia coli. Water Research, 2013, 47, 3026-3036.	5.3	80
234	Indeterminate tcdB using a Clostridium difficile PCR assay: a retrospective cohort study. BMC Infectious Diseases, 2013, 13, 324.	1.3	4

#	Article	IF	CITATIONS
235	Understanding the burden of influenza infection among adults in Canadian hospitals: A comparison of the 2009-2010 pandemic season with the prepandemic and postpandemic seasons. American Journal of Infection Control, 2013, 41, 1032-1037.	1.1	18
236	Have changing pneumococcal vaccination programmes impacted disease in Ontario?. Vaccine, 2013, 31, 2680-2685.	1.7	15
237	Hospital Outbreak of Middle East Respiratory Syndrome Coronavirus. New England Journal of Medicine, 2013, 369, 407-416.	13.9	1,044
238	Evaluation of 2009 pandemic H1N1 influenza vaccination in adults with lymphoid malignancies receiving chemotherapy or following autologous stem cell transplant. Leukemia and Lymphoma, 2013, 54, 1387-1395.	0.6	17
239	Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995–2011. Vaccine, 2013, 31, 5863-5871.	1.7	62
240	Prevalence of Colonization and Infection with Methicillin-Resistant <i>Staphylococcus aureus</i> and Vancomycin-Resistant <i>Enterococcus</i> and of <i>Clostridium difficile</i> Infection in Canadian Hospitals. Infection Control and Hospital Epidemiology, 2013, 34, 687-693.	1.0	34
241	Measuring influenza immunization coverage among health care workers in acute care hospitals and continuing care organizations in Canada. American Journal of Infection Control, 2013, 41, 340-344.	1.1	5
242	Risk Factors for Influenza among Health Care Workers during 2009 Pandemic, Toronto, Ontario, Canada. Emerging Infectious Diseases, 2013, 19, 606-615.	2.0	32
243	Risk of Guillain-Barr $ ilde{A}$ © syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study. Lancet Infectious Diseases, The, 2013, 13, 769-776.	4.6	87
244	Serotype distribution of invasive <i>Streptococcus pneumoniae</i> in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010–2012. Canadian Journal of Microbiology, 2013, 59, 778-788.	0.8	99
245	Behind the mask: Determinants of nurse's adherence to facial protective equipment. American Journal of Infection Control, 2013, 41, 8-13.	1.1	69
246	Downstream Impact of Urine Cultures Ordered without Indication at Two Acute Care Teaching Hospitals. Infection Control and Hospital Epidemiology, 2013, 34, 1113-1114.	1.0	38
247	An observational study of the hand hygiene initiative: a comparison of preintervention and postintervention outcomes. BMJ Open, 2013, 3, e003018.	0.8	23
248	Cardiac complications of influenza infection in 3 adults. Cmaj, 2013, 185, 581-584.	0.9	5
249	Molecular epidemiology of vancomycin-resistant enterococcal bacteraemia: results from the Canadian Nosocomial Infection Surveillance Program, 1999-2009. Journal of Antimicrobial Chemotherapy, 2013, 68, 1505-1509.	1.3	51
250	Statistical estimates of respiratory admissions attributable to seasonal and pandemic influenza for Canada. Influenza and Other Respiratory Viruses, 2013, 7, 799-808.	1.5	47
251	The Occurrence and Impact of Bacterial Organisms Complicating Critical Care Illness Associated With 2009 Influenza A(H1N1) Infection. Chest, 2013, 144, 39-47.	0.4	34
252	Epidemiology and Outcome of Pneumonia Caused by Methicillin-Resistant Staphylococcus aureus (MRSA) in Canadian Hospitals. PLoS ONE, 2013, 8, e75171.	1.1	37

#	Article	IF	Citations
253	Methicillin-Resistant <i>Staphylococcus aureus</i> Colonization among Health Care Workers in a Downtown Emergency Department in Toronto, Ontario. Canadian Journal of Infectious Diseases and Medical Microbiology, 2013, 24, e57-e60.	0.7	7
254	Prevalence and Incidence of Antimicrobial-Resistant Organisms among Hospitalized Inflammatory Bowel Disease Patients. Canadian Journal of Infectious Diseases and Medical Microbiology, 2013, 24, e117-e121.	0.7	8
255	Efficacy of Admission Screening for Extended-Spectrum Beta-Lactamase Producing Enterobacteriaceae. PLoS ONE, 2013, 8, e62678.	1.1	22
256	Risk of infection following a visit to the emergency department: a cohort study. Cmaj, 2012, 184, E232-E239.	0.9	54
257	Outbreak of Carbapenem-Resistant Enterobacteriaceae Containing blaNDM-1, Ontario, Canada. Clinical Infectious Diseases, 2012, 55, e109-e117.	2.9	109
258	Emergency department visits and infections. Cmaj, 2012, 184, 678.3-679.	0.9	2
259	Carbapenem-resistant Gram-negative bacilli in Canada 2009-10: results from the Canadian Nosocomial Infection Surveillance Program (CNISP). Journal of Antimicrobial Chemotherapy, 2012, 67, 1359-1367.	1.3	80
260	Outbreak of Extended-Spectrum β-Lactamase–producing <i>Klebsiella oxytoca</i> Infections Associated with Contaminated Handwashing Sinks1. Emerging Infectious Diseases, 2012, 18, 1242-1247.	2.0	153
261	The Social Determinants of Health and Pandemic H1N1 2009 Influenza Severity. American Journal of Public Health, 2012, 102, e51-e58.	1.5	103
262	Maternal Antibiotic Exposure and Risk of Antibiotic Resistance in Neonatal Early-onset Sepsis. Pediatric Infectious Disease Journal, 2012, 31, 1206-1208.	1.1	14
263	Laboratory-Confirmed Pandemic H1N1 Influenza in Hospitalized Adults: Findings from the Canadian Nosocomial Infections Surveillance Program, 2009-2010. Infection Control and Hospital Epidemiology, 2012, 33, 1043-1046.	1.0	8
264	The role of drinking water in the transmission of antimicrobial-resistant <i>E. coli</i> . Epidemiology and Infection, 2012, 140, 633-642.	1.0	54
265	Decreased Susceptibility to Noncarbapenem Antimicrobials in Extended-Spectrum-Î ² -Lactamase-Producing Escherichia coli and Klebsiella pneumoniae Isolates in Toronto, Canada. Antimicrobial Agents and Chemotherapy, 2012, 56, 3977-3980.	1.4	19
266	A randomized control trial comparing immunogenicity, safety, and preference for self-versus nurse-administered intradermal influenza vaccine. Vaccine, 2012, 30, 6287-6293.	1.7	31
267	Serotype distribution of invasive Streptococcus pneumoniae in Canada during the introduction of the 13-valent pneumococcal conjugate vaccine, 2010. Canadian Journal of Microbiology, 2012, 58, 1008-1017.	0.8	19
268	Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18–55 years of age. Vaccine, 2012, 30, 2556-2563.	1.7	107
269	Disparity in infection control practices for multidrug-resistant Enterobacteriaceae. American Journal of Infection Control, 2012, 40, 836-839.	1.1	23
270	Prevalence and predictors of MRSA, ESBL, and VRE colonization in the ambulatory IBD population. Journal of Crohn's and Colitis, 2012, 6, 743-749.	0.6	20

#	Article	IF	CITATIONS
271	AMMI Canada Position Paper: 2012 Mandatory Influenza Immunization of Health Care Workers. Canadian Journal of Infectious Diseases and Medical Microbiology, 2012, 23, e93-e95.	0.7	10
272	Immunogenicity of a half-dose of adjuvanted 2009 pandemic H1N1 influenza vaccine in adults: a prospective cohort study. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31, 591-597.	1.3	1
273	Short and Long-Term Safety of the 2009 AS03-Adjuvanted Pandemic Vaccine. PLoS ONE, 2012, 7, e38563.	1.1	16
274	The Impact of Infection on Population Health: Results of the Ontario Burden of Infectious Diseases Study. PLoS ONE, 2012, 7, e44103.	1.1	106
275	Distribution of Antiseptic Resistance Genes <i>qacA, qacB</i> , and <i>smr</i> in Methicillin-Resistant Staphylococcus aureus Isolated in Toronto, Canada, from 2005 to 2009. Antimicrobial Agents and Chemotherapy, 2011, 55, 2999-3001.	1.4	84
276	Effect of Patterns of Transferring Patients among Healthcare Institutions on Rates of Nosocomial Methicillin-Resistant <i>Staphylococcus aureus</i> Transmission: A Monte Carlo Simulation. Infection Control and Hospital Epidemiology, 2011, 32, 136-147.	1.0	33
277	Increased Prevalence of Methicillin-Sensitive Staphylococcus Aureus and Extended Spectrum Beta-Lactamase Bacteria Colonization Among Inflammatory Bowel Disease Outpatients. Gastroenterology, 2011, 140, S-736.	0.6	0
278	Infection prevention and control practices related to Clostridium difficile infection in Canadian acute and long-term care institutions. American Journal of Infection Control, 2011, 39, 177-182.	1.1	10
279	A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness. Vaccine, 2011, 29, 1921-1928.	1.7	28
280	When should a diagnosis of influenza be considered in adults requiring intensive care unit admission? Results of population-based active surveillance in Toronto. Critical Care, 2011, 15, R182.	2.5	18
281	The Impact of Influenza on the Canadian First Nations. Canadian Journal of Public Health, 2011, 102, 345-348.	1.1	25
282	Self-Collected Mid-Turbinate Swabs for the Detection of Respiratory Viruses in Adults with Acute Respiratory Illnesses. PLoS ONE, 2011, 6, e21335.	1.1	69
283	Seroprevalence of Pandemic Influenza H1N1 in Ontario from January 2009–May 2010. PLoS ONE, 2011, 6, e26427.	1.1	23
284	Another Look at the Human Papillomavirus Vaccine Experience in Canada. American Journal of Public Health, 2011, 101, 1850-1857.	1.5	6
285	A Comparison Of The First And Second Waves Of H1N1-Related Critical Illness In Canada. , 2011, , .		0
286	H1N1 in Pregnancy: A Tertiary Care Centre Experience. Journal of Obstetrics and Gynaecology Canada, 2011, 33, 698-704.	0.3	8
287	Respiratory illnesses in Canadian health care workers: a pilot study of influenza vaccine and oseltamivir prophylaxis during the 2007/2008 influenza season. Influenza and Other Respiratory Viruses, 2011, 5, 404-408.	1.5	8
288	644: Knowledge about H1N1 influenza and the vaccine impacts vaccination uptake among pregnant women. American Journal of Obstetrics and Gynecology, 2011, 204, S255.	0.7	0

#	Article	IF	CITATIONS
289	New Delhi metallo-Â-lactamase-1 in Enterobacteriaceae: emerging resistance. Cmaj, 2011, 183, 59-64.	0.9	35
290	Novel Mutations in a Patient Isolate of Streptococcus agalactiae with Reduced Penicillin Susceptibility Emerging after Long-Term Oral Suppressive Therapy. Antimicrobial Agents and Chemotherapy, 2011, 55, 2983-2985.	1.4	80
291	Systemic Dysregulation of Angiopoietin-1 and -2 in Streptococcal Toxic Shock Syndrome. Clinical Infectious Diseases, 2011, 52, e157-e161.	2.9	21
292	New Delhi metallo-Â-lactamase-1: local acquisition in Ontario, Canada, and challenges in detection. Cmaj, 2011, 183, 1257-1261.	0.9	37
293	Susceptibility of <i>Streptococcus pneumoniae</i> to Fluoroquinolones in Canada. Antimicrobial Agents and Chemotherapy, 2011, 55, 3703-3708.	1.4	57
294	Evaluation of Coseasonality of Influenza and Invasive Pneumococcal Disease: Results from Prospective Surveillance. PLoS Medicine, 2011, 8, e1001042.	3.9	43
295	Predictors of pandemic influenza infection in adults presenting to two urban emergency departments, Toronto, 2009. Canadian Journal of Emergency Medicine, 2011, 13, 7-12.	0.5	10
296	Incidence of Influenza in Healthy Adults and Healthcare Workers: A Systematic Review and Meta-Analysis. PLoS ONE, 2011, 6, e26239.	1.1	184
297	Update on herpes zoster vaccination: a family practitioner's guide. Canadian Family Physician, 2011, 57, 1127-31.	0.1	20
298	Laboratory diagnosis of 2009 H1N1 influenza A virus. Critical Care Medicine, 2010, 38, e38-e42.	0.4	15
299	Review: Extended-duration chemoprophylaxis with neuraminidase inhibitors prevents symptomatic influenza. Annals of Internal Medicine, 2010, 152, JC3.	2.0	0
300	Epidemiology of influenza-associated hospitalization in adults, Toronto, 2007/8. European Journal of Clinical Microbiology and Infectious Diseases, 2010, 29, 835-843.	1.3	15
301	Physicians and hand hygiene practice: a focus group study. Journal of Hospital Infection, 2010, 76, 87-89.	1.4	17
302	Towards the Photonic Nose: A Novel Platform for Molecule and Bacteria Identification. Advanced Materials, 2010, 22, 1351-1354.	11.1	163
303	Characterization of the quinolone resistant determining regions in clinical isolates of pneumococci collected in Canada. Annals of Clinical Microbiology and Antimicrobials, 2010, 9, 3.	1.7	10
304	Respiratory Virus Infection and Risk of Invasive Meningococcal Disease in Central Ontario, Canada. PLoS ONE, 2010, 5, e15493.	1.1	26
305	Health Care–Associated <i>Clostridium difficile</i> Infection in Canada: Patient Age and Infecting Strain Type Are Highly Predictive of Severe Outcome and Mortality. Clinical Infectious Diseases, 2010, 50, 194-201.	2.9	259
306	High Prevalence of ST131 Isolates Producing CTX-M-15 and CTX-M-14 among Extended-Spectrum-Î ² -Lactamase-Producing <i>Escherichia coli</i> lsolates from Canada. Antimicrobial Agents and Chemotherapy, 2010, 54, 1327-1330.	1.4	101

#	Article	IF	CITATIONS
307	Epidemic of Group A <i>Streptococcus</i> M/ <i>emm</i> 59 Causing Invasive Disease in Canada. Clinical Infectious Diseases, 2010, 51, 1290-1297.	2.9	46
308	Antimicrobial Susceptibilities of Health Care-Associated and Community-Associated Strains of Methicillin-Resistant <i>Staphylococcus aureus</i> from Hospitalized Patients in Canada, 1995 to 2008. Antimicrobial Agents and Chemotherapy, 2010, 54, 2265-2268.	1.4	20
309	Detection and Characterization of Heterogeneous Vancomycin-Intermediate <i>Staphylococcus aureus</i> Isolates in Canada: Results from the Canadian Nosocomial Infection Surveillance Program, 1995-2006. Antimicrobial Agents and Chemotherapy, 2010, 54, 945-949.	1.4	44
310	Decreased necrotizing fasciitis capacity caused by a single nucleotide mutation that alters a multiple gene virulence axis. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 888-893.	3.3	99
311	Molecular complexity of successive bacterial epidemics deconvoluted by comparative pathogenomics. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 4371-4376.	3.3	153
312	Economic Appraisal of Ontario's Universal Influenza Immunization Program: A Cost-Utility Analysis. PLoS Medicine, 2010, 7, e1000256.	3.9	71
313	Pandemic (H1N1) 2009: assessing the response. Cmaj, 2010, 182, 1874-1878.	0.9	15
314	Focus Group Study of Hand Hygiene Practice among Healthcare Workers in a Teaching Hospital in Toronto, Canada. Infection Control and Hospital Epidemiology, 2010, 31, 144-150.	1.0	121
315	Methicillin-Resistant <i>Staphylococcus aureus</i> Colonization or Infection in Canada: National Surveillance and Changing Epidemiology, 1995–2007. Infection Control and Hospital Epidemiology, 2010, 31, 348-356.	1.0	78
316	Molecular characterization of moxifloxacin resistance from Canadian Clostridium difficile clinical isolates. Diagnostic Microbiology and Infectious Disease, 2010, 66, 419-424.	0.8	30
317	Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Evidence from the Canadian Experience. Vaccine, 2010, 28, 6210-6220.	1.7	46
318	Evaluation of Pneumonia Severity and Acute Physiology Scores to Predict ICU Admission and Mortality in Patients Hospitalized for Influenza. PLoS ONE, 2010, 5, e9563.	1.1	42
319	Risk Factors for SARS Transmission from Patients Requiring Intubation: A Multicentre Investigation in Toronto, Canada. PLoS ONE, 2010, 5, e10717.	1.1	252
320	Update on the Use of Conjugate Pneumococcal Vaccines in Childhood. Canada Communicable Disease Report, 2010, 36, 1-21.	0.6	24
321	Hypervirulent <i>Clostridium difficile</i> Strains in Hospitalized Patients, Canada1. Emerging Infectious Diseases, 2010, 16, 678-681.	2.0	53
322	Compulsory School-Entry Vaccination Laws and Exemptions: Who Is Opting Out in Ontario and Why Does It Matter?. Healthcare Policy, 2010, 5, 37-46.	0.3	1
323	Compulsory school-entry vaccination laws and exemptions: who is opting out in ontario and why does it matter?. Healthcare Policy, 2010, 5, 37-46.	0.3	3
324	Community-associated methicillin-resistant Staphylococcus aureus: prevalence in skin and soft tissue infections at emergency departments in the Greater Toronto Area and associated risk factors. Canadian Journal of Emergency Medicine, 2009, 11, 439-446.	0.5	24

#	Article	IF	CITATIONS
325	Population-Based Surveillance for Invasive Pneumococcal Disease in Homeless Adults in Toronto. PLoS ONE, 2009, 4, e7255.	1.1	41
326	Characterization of Cefoxitin-Resistant <i>Escherichia coli</i> Isolates from Recreational Beaches and Private Drinking Water in Canada between 2004 and 2006. Antimicrobial Agents and Chemotherapy, 2009, 53, 3126-3130.	1.4	37
327	Seasonal Influenza in Adults and Children—Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management: Clinical Practice Guidelines of the Infectious Diseases Society of America. Clinical Infectious Diseases, 2009, 48, 1003-1032.	2.9	604
328	Health Care–Associated <i>Clostridium difficile</i> Infection in Adults Admitted to Acute Care Hospitals in Canada: A Canadian Nosocomial Infection Surveillance Program Study. Clinical Infectious Diseases, 2009, 48, 568-576.	2.9	243
329	Diagnostic Testing or Empirical Therapy for Patients Hospitalized with Suspected Influenza: What to Do?. Clinical Infectious Diseases, 2009, 48, S14-S19.	2.9	34
330	Assessing the Impact of Intravenous Immunoglobulin in the Management of Streptococcal Toxic Shock Syndrome: A Noble but Difficult Quest. Clinical Infectious Diseases, 2009, 49, 1377-1379.	2.9	22
331	In vitro activity of ceftaroline, ceftobiprole and cethromycin against clinical isolates of Streptococcus pneumoniae collected from across Canada between 2003 and 2008. Journal of Antimicrobial Chemotherapy, 2009, 64, 659-660.	1.3	33
332	Genome-wide dissection of globally emergent multi-drug resistant serotype 19A Streptococcus pneumoniae. BMC Genomics, 2009, 10, 642.	1.2	98
333	Pneumococcal Pneumonia: Potential for Diagnosis through a Urinary Metabolic Profile. Journal of Proteome Research, 2009, 8, 5550-5558.	1.8	93
334	A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults ≥65 years of age. Vaccine, 2009, 27, 5913-5919.	1.7	53
335	Management guidelines for obstetric patients and neonates born to mothers with suspected or probable severe acute respiratory syndrome (SARS). International Journal of Gynecology and Obstetrics, 2009, 107, 82-86.	1.0	5
336	Infection control practices related to Clostridium difficile infection in acute care hospitals in Canada. American Journal of Infection Control, 2009, 37, 9-14.	1.1	22
337	Infection with H274Y-positive influenza A (H1N1) is not associated with a change in nasopharyngeal Streptococcus pneumoniae colonization in patients. International Journal of Infectious Diseases, 2009, 13, e321-e322.	1.5	O
338	Impact of a Mandatory Infection Control Education Program on Nosocomial Acquisition of Methicillin-Resistant < i>Staphylococcus aureus < /i>Infection Control and Hospital Epidemiology, 2009, 30, 249-256.	1.0	18
339	Management Guidelines for Obstetric Patients and Neonates Born to Mothers With Suspected or Probable Severe Acute Respiratory Syndrome (SARS). Journal of Obstetrics and Gynaecology Canada, 2009, 31, 358-364.	0.3	48
340	Lignes directrices quant à la prise en charge des patientes en obstà ©trique chez lesquelles la prà ©sence du syndrome respiratoire aigu sà © và "re (SRAS) est soupà § onnà © e ou probable, et des nouveau-nà © s issus de ces patientes. Journal of Obstetrics and Gynaecology Canada, 2009, 31, 365-372.	0.3	0
341	Is a Mass Immunization Program for Pandemic (H1N1) 2009 Good Value for Money? Early Evidence from the Canadian Experience PLOS Currents, 2009, 1, RRN1137.	1.4	4
342	167: Prevalence and Characterization of Community-Acquired Methicillin Resistant Staphylococcus Aureus Colonization in High-Risk Individuals in Toronto. Annals of Emergency Medicine, 2008, 51, 521-522.	0.3	2

#	Article	IF	Citations
343	Invasive pneumococcal disease in adult hematopoietic stem cell transplant recipients: a decade of prospective population-based surveillance. Bone Marrow Transplantation, 2008, 41, 743-747.	1.3	82
344	The individual, environmental, and organizational factors that influence nurses' use of facial protection to prevent occupational transmission of communicable respiratory illness in acute care hospitals. American Journal of Infection Control, 2008, 36, 481-487.	1.1	66
345	Impact of public vaccination programs on adult vaccination rates: Two examples from Ontario, Canada. Vaccine, 2008, 26, 1432-1437.	1.7	18
346	Factors Associated With Acquisition of Vancomycin-Resistant Enterococci (VRE) in Roommate Contacts of Patients Colonized or Infected with VRE in a Tertiary Care Hospital. Infection Control and Hospital Epidemiology, 2008, 29, 398-403.	1.0	37
347	Risk Factors for Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA) Acquisition in Roommate Contacts of Patients Colonized or Infected With MRSA in an Acute-Care Hospital. Infection Control and Hospital Epidemiology, 2008, 29, 600-606.	1.0	58
348	Dietary Intake of Elderly Living In Toronto Long-Term Care Facilities: Comparison with the Dietary Reference Intake: Response to Klevay. Rejuvenation Research, 2008, 11, 699-700.	0.9	1
349	At the Threshold: Defining Clinically Meaningful Resistance Thresholds for Antibiotic Choice in Communityâ€Acquired Pneumonia. Clinical Infectious Diseases, 2008, 46, 1131-1138.	2.9	43
350	Neonatal group B streptococcal disease: Incidence, presentation, and mortality. Journal of Maternal-Fetal and Neonatal Medicine, 2008, 21, 53-57.	0.7	39
351	Reply to Chanâ€Tack and Murray. Clinical Infectious Diseases, 2008, 46, 1629-1630.	2.9	0
352	Characterization of Clostridium difficile Strains Isolated from Patients in Ontario, Canada, from 2004 to 2006. Journal of Clinical Microbiology, 2008, 46, 2999-3004.	1.8	84
353	A Cross-Sectional Study of Maternity Care Providers' and Women's Knowledge, Attitudes, and Behaviours Towards Influenza Vaccination During Pregnancy. Journal of Obstetrics and Gynaecology Canada, 2008, 30, 404-410.	0.3	117
354	Antimalarial Therapy Selection for Quinolone Resistance among Escherichia coli in the Absence of Quinolone Exposure, in Tropical South America. PLoS ONE, 2008, 3, e2727.	1.1	22
355	The Effect of Universal Influenza Immunization on Mortality and Health Care Use. PLoS Medicine, 2008, 5, e211.	3.9	138
356	Randomized Controlled Trial of Chlorhexidine Gluconate for Washing, Intranasal Mupirocin, and Rifampin and Doxycycline Versus No Treatment for the Eradication of Methicillin-Resistant Staphylococcus aureus Colonization. Clinical Infectious Diseases, 2007, 44, 178-185.	2.9	253
357	Antiviral Therapy and Outcomes of Influenza Requiring Hospitalization in Ontario, Canada. Clinical Infectious Diseases, 2007, 45, 1568-1575.	2.9	344
358	Alternative Methods of Estimating an Incubation Distribution. Epidemiology, 2007, 18, 253-259.	1.2	72
359	Severe Acute Respiratory Syndrome (SARS) Coronavirus. Seminars in Respiratory and Critical Care Medicine, 2007, 28, 201-212.	0.8	10
360	Dietary Intake of Elderly Living in Toronto Long-Term Care Facilities: Comparison to the Dietary Reference Intake. Rejuvenation Research, 2007, 10, 301-310.	0.9	41

#	Article	IF	CITATIONS
361	Antivirals and the Control of Influenza Outbreaks. Clinical Infectious Diseases, 2007, 45, 1362-1368.	2.9	48
362	Comparative Genomics of Canadian Epidemic Lineages of Methicillin-Resistant Staphylococcus aureus. Journal of Clinical Microbiology, 2007, 45, 1904-1911.	1.8	93
363	Mupirocin-Resistant, Methicillin-Resistant Staphylococcus aureus Strains in Canadian Hospitals. Antimicrobial Agents and Chemotherapy, 2007, 51, 3880-3886.	1.4	148
364	Interferon-Mediated Immunopathological Events Are Associated with Atypical Innate and Adaptive Immune Responses in Patients with Severe Acute Respiratory Syndrome. Journal of Virology, 2007, 81, 8692-8706.	1.5	353
365	Necrotizing pneumonia and septic shock: suspecting CA-MRSA in patients presenting to Canadian emergency departments. Canadian Journal of Emergency Medicine, 2007, 9, 300-303.	0.5	30
366	Appropriate measures of influenza immunization program effectiveness. Vaccine, 2007, 25, 967-969.	1.7	4
367	Surveillance for Hospital Outbreaks of Invasive Group A Streptococcal Infections in Ontario, Canada, 1992 to 2000. Annals of Internal Medicine, 2007, 147, 234.	2.0	44
368	Factors Associated With Critical-Care Healthcare Workers' Adherence to Recommended Barrier Precautions During the Toronto Severe Acute Respiratory Syndrome Outbreak. Infection Control and Hospital Epidemiology, 2007, 28, 1275-1283.	1.0	49
369	Group a Streptococcal Carriage among Residents of an Urban Homeless Shelter. Canadian Journal of Infectious Diseases and Medical Microbiology, 2007, 18, 316-317.	0.7	4
370	A Nosocomial Outbreak of Community-Associated Methicillin-Resistant <i>Staphylococcus aureus</i> aureusand Postpartum Mothers. Canadian Journal of Infectious Diseases and Medical Microbiology, 2007, 18, 128-132.	0.7	19
371	Effect of Multivitamin and Mineral Supplementation on Episodes of Infection in Nursing Home Residents: A Randomized, Placebo-Controlled Study. Journal of the American Geriatrics Society, 2007, 55, 35-42.	1.3	48
372	RESPONSE LETTER TO DR. HEMILÃ,,. Journal of the American Geriatrics Society, 2007, 55, 1313-1314.	1.3	0
373	ampCgene expression in promoter mutants of cefoxitin-resistantEscherichia coliclinical isolates. FEMS Microbiology Letters, 2007, 270, 265-271.	0.7	68
374	Adverse Events Associated with High-Dose Ribavirin: Evidence from the Toronto Outbreak of Severe Acute Respiratory Syndrome. Pharmacotherapy, 2007, 27, 494-503.	1.2	62
375	Invasive Pneumococcal Disease in Solid Organ Transplant Recipients?10-Year Prospective Population Surveillance. American Journal of Transplantation, 2007, 7, 1209-1214.	2.6	109
376	Review: Trials of injectable pneumococcal vaccines do not show effectiveness in chronic obstructive pulmonary disease. ACP Journal Club, 2007, 146, 36.	0.1	0
377	Review: trials of injectable pneumococcal vaccines do not show effectiveness in chronic obstructive pulmonary disease. ACP Journal Club, 2007, 146, 36.	0.1	0
378	Methicillin-ResistantStaphylococcus aureusin Canadian Aboriginal People. Infection Control and Hospital Epidemiology, 2006, 27, 204-207.	1.0	26

#	Article	IF	Citations
379	Accuracy of Healthcare Worker Recall and Medical Record Review for Identifying Infectious Exposures to Hospitalized Patients. Infection Control and Hospital Epidemiology, 2006, 27, 722-728.	1.0	3
380	Cluster of Cases of Severe Acute Respiratory Syndrome Among Toronto Healthcare Workers After Implementation of Infection Control Precautions: A Case Series. Infection Control and Hospital Epidemiology, 2006, 27, 473-478.	1.0	75
381	Coordinated Response to SARS, Vancouver, Canada. Emerging Infectious Diseases, 2006, 12, 155-158.	2.0	28
382	Addressing the Emergence of Pediatric Vaccination Concerns. Canadian Journal of Public Health, 2006, 97, 139-141.	1.1	2
383	Impact of Antibiotic Administrative Restrictions on Trends in Antibiotic Resistance. Canadian Journal of Public Health, 2006, 97, 126-131.	1.1	11
384	Morbidity and Mortality of Patients With Invasive Group A Streptococcal Infections Admitted to the ICU. Chest, 2006, 130, 1679-1686.	0.4	49
385	Febrile respiratory illness in the intensive care unit setting: an infection control perspective. Current Opinion in Critical Care, 2006, 12, 37-42.	1.6	24
386	OVERDIAGNOSIS OF ASTHMA AND ITS RELATIONSHIP TO BODY MASS INDEX. Chest, 2006, 130, 97S.	0.4	43
387	Viable Group A Streptococci in Macrophages during Acute Soft Tissue Infection. PLoS Medicine, 2006, 3, e53.	3.9	126
388	Early diagnosis of SARS: lessons from the Toronto SARS outbreak. European Journal of Clinical Microbiology and Infectious Diseases, 2006, 25, 230-237.	1.3	38
389	An outbreak of methicillin-resistant Staphylococcus aureus skin infections resulting from horse to human transmission in a veterinary hospital. Veterinary Microbiology, 2006, 114, 160-164.	0.8	145
390	Suspected transmission of methicillin-resistant Staphylococcus aureus between domestic pets and humans in veterinary clinics and in the household. Veterinary Microbiology, 2006, 115, 148-155.	0.8	240
391	A survey of physician's attitudes regarding management of severe group A streptococcal infections. Scandinavian Journal of Infectious Diseases, 2006, 38, 977-982.	1.5	13
392	Guillain-Barré Syndrome After Influenza Vaccination in Adults. Archives of Internal Medicine, 2006, 166, 2217.	4.3	172
393	Verification of the IDI-MRSA Assay for Detecting Methicillin-Resistant Staphylococcus aureus in Diverse Specimen Types in a Core Clinical Laboratory Setting. Journal of Clinical Microbiology, 2006, 44, 3794-3796.	1.8	46
394	Macrolide Resistance in Bacteremic Pneumococcal Disease: Implications for Patient Management. Clinical Infectious Diseases, 2006, 43, 432-438.	2.9	144
395	Methicillin-resistant Staphylococcus Aureus in Horses at a Veterinary Teaching Hospital: Frequency, Characterization, and Association with Clinical Disease. Journal of Veterinary Internal Medicine, 2006, 20, 182.	0.6	93
396	Methicillin-resistant <i>Staphylococcus aureus</i> Colonization in Veterinary Personnel. Emerging Infectious Diseases, 2006, 12, 1933-1938.	2.0	151

#	Article	IF	CITATIONS
397	Economic Evaluation of Oseltamivir Phosphate for Postexposure Prophylaxis of Influenza in Long-Term Care Facilities. Journal of the American Geriatrics Society, 2005, 53, 444-451.	1.3	25
398	Drug-resistant pneumococcal pneumonia: clinical relevance and approach to management. European Journal of Clinical Microbiology and Infectious Diseases, 2005, 24, 780-788.	1.3	51
399	Patient Contact Recall after SARS Exposure. Emerging Infectious Diseases, 2005, 11, 625-628.	2.0	3
400	Risk Factors for Pediatric Invasive Group A Streptococcal Disease. Emerging Infectious Diseases, 2005, 11, 1062-1066.	2.0	67
401	Methicillin-resistant <i>Staphylococcus aureus</i> in Horses and Horse Personnel, 2000–2002. Emerging Infectious Diseases, 2005, 11, 430-435.	2.0	214
402	Effect of a multifaceted intervention on number of antimicrobial prescriptions for suspected urinary tract infections in residents of nursing homes: cluster randomised controlled trial. BMJ: British Medical Journal, 2005, 331, 669.	2.4	251
403	Detection of Airborne Severe Acute Respiratory Syndrome (SARS) Coronavirus and Environmental Contamination in SARS Outbreak Units. Journal of Infectious Diseases, 2005, 191, 1472-1477.	1.9	358
404	Genetic Diversity among Type emm28 Group A Streptococcus Strains Causing Invasive Infections and Pharyngitis. Journal of Clinical Microbiology, 2005, 43, 4083-4091.	1.8	52
405	Use of a Selective Enrichment Broth To Recover Clostridium difficile from Stool Swabs Stored under Different Conditions. Journal of Clinical Microbiology, 2005, 43, 5341-5343.	1.8	78
406	Can Routine Laboratory Tests Discriminate between Severe Acute Respiratory Syndrome and Other Causes of Communityâ€Acquired Pneumonia?. Clinical Infectious Diseases, 2005, 40, 1079-1086.	2.9	130
407	Hospital-Acquired Invasive Group A Streptococcal Infections in Ontario, Canada, 1992-2000. Clinical Infectious Diseases, 2005, 41, 334-342.	2.9	40
408	Does isolation prevent the spread of methicillin-resistant Staphylococcus aureus?. Cmaj, 2005, 172, 875-875.	0.9	0
409	Prevalence and Characterization of Invasive Isolates of Streptococcus pyogenes with Reduced Susceptibility to Fluoroquinolones. Antimicrobial Agents and Chemotherapy, 2005, 49, 2130-2132.	1.4	17
410	Identification of a Progenitor of the CTX-M-9 Group of Extended-Spectrum β-Lactamases from Kluyvera georgiana Isolated in Guyana. Antimicrobial Agents and Chemotherapy, 2005, 49, 2112-2115.	1.4	103
411	Mosaic Prophages with Horizontally Acquired Genes Account for the Emergence and Diversification of the Globally Disseminated M1T1 Clone of Streptococcus pyogenes. Journal of Bacteriology, 2005, 187, 3311-3318.	1.0	109
412	Predicting Antimicrobial Resistance in Invasive Pneumococcal Infections. Clinical Infectious Diseases, 2005, 40, 1288-1297.	2.9	239
413	Decreased Prevalence of Virulence Factors among Ciprofloxacin-Resistant Uropathogenic Escherichia coli Isolates. Journal of Clinical Microbiology, 2005, 43, 4218-4220.	1.8	45
414	Community-associated methicillin-resistant Staphylococcus aureus in horses and humans who work with horses. Journal of the American Veterinary Medical Association, 2005, 226, 580-583.	0.2	147

#	Article	IF	Citations
415	Clinical and Epidemiologic Features of Methicillin-Resistant Staphylococcus aureus in Elderly Hospitalized Patients. Infection Control and Hospital Epidemiology, 2005, 26, 838-841.	1.0	22
416	Nosocomial Acquisition of Methicillin-ResistantStaphylococcus aureusDuring an Outbreak of Severe Acute Respiratory Syndrome. Infection Control and Hospital Epidemiology, 2005, 26, 134-137.	1.0	13
417	Modeling Transmission of Methicillin-ResistantStaphylococcus AureusAmong Patients Admitted to a Hospital. Infection Control and Hospital Epidemiology, 2005, 26, 607-615.	1.0	92
418	Successful management of severe group A streptococcal soft tissue infections using an aggressive medical regimen including intravenous polyspecific immunoglobulin together with a conservative surgical approach. Scandinavian Journal of Infectious Diseases, 2005, 37, 166-172.	1.5	156
419	Beliefs and practices of Ontario midwives about influenza immunization. Vaccine, 2005, 23, 1574-1578.	1.7	38
420	SARS among Critical Care Nurses, Toronto. Emerging Infectious Diseases, 2004, 10, 251-255.	2.0	293
421	Nursing Home Residents and <i>Enterobacteriaceae </i> Resistant to Third-Generation Cephalosporins. Emerging Infectious Diseases, 2004, 10, 1050-1055.	2.0	17
422	Hospital Preparedness and SARS. Emerging Infectious Diseases, 2004, 10, 771-776.	2.0	83
423	SARS in Healthcare Facilities, Toronto and Taiwan. Emerging Infectious Diseases, 2004, 10, 777-781.	2.0	148
424	Enterococcus faecium NO3-0072 carries a new VanD-type vancomycin resistance determinant: characterization of the VanD5 operon. Journal of Antimicrobial Chemotherapy, 2004, 54, 680-683.	1.3	38
425	Clostridium difficile infection in hospitals: a brewing storm. Cmaj, 2004, 171, 27-29.	0.9	46
426	SARS outbreak in the Greater Toronto Area: the emergency department experience. Cmaj, 2004, 171, 1342-1344.	0.9	21
427	Genome-wide molecular dissection of serotype M3 group A Streptococcus strains causing two epidemics of invasive infections. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 11833-11838.	3.3	121
428	Let Him Who Desires Peace Prepare for War: United States Hospitals and Severe Acute Respiratory Syndrome Preparedness. Clinical Infectious Diseases, 2004, 39, 275-277.	2.9	0
429	Health Care Workers and the Initiation of Treatment for Latent Tuberculosis Infection. Clinical Infectious Diseases, 2004, 39, 667-672.	2.9	33
430	Complete Nucleotide Sequence of a 92-Kilobase Plasmid Harboring the CTX-M-15 Extended-Spectrum Beta-Lactamase Involved in an Outbreak in Long-Term-Care Facilities in Toronto, Canada. Antimicrobial Agents and Chemotherapy, 2004, 48, 3758-3764.	1.4	316
431	In Vitro Antimicrobial Susceptibilities of Streptococcus pneumoniae Clinical Isolates Obtained in Canada in 2002. Antimicrobial Agents and Chemotherapy, 2004, 48, 3305-3311.	1.4	64
432	Nutrition Risk Factors for Survival in the Elderly Living in Canadian Long-Term Care Facilities. Journal of the American Geriatrics Society, 2004, 52, 59-65.	1.3	64

#	Article	IF	CITATIONS
433	Transmission and control of SARS. Current Infectious Disease Reports, 2004, 6, 220-227.	1.3	26
434	Adverse Effects of Amantadine and Oseltamivir Used During Respiratory Outbreaks in a Center for Developmentally Disabled Adults. Infection Control and Hospital Epidemiology, 2004, 25, 955-961.	1.0	13
435	News in Antimicrobial Resistance: Documenting the Progress of Pathogens. Infection Control and Hospital Epidemiology, 2004, 25, 97-98.	1.0	4
436	Facility-Level Correlates of Antimicrobial Use in Nursing Homes. Infection Control and Hospital Epidemiology, 2004, 25, 173-176.	1.0	4
437	Patterns of Handwashing Behavior and Visits to Patients on a General Medical Ward of Healthcare Workers. Infection Control and Hospital Epidemiology, 2004, 25, 198-202.	1.0	38
438	Severe Invasive Group a Streptococcal Infections. , 2004, , 3-33.		4
439	Interpretation of diagnostic laboratory tests for severe acute respiratory syndrome: the Toronto experience. Cmaj, 2004, 170, 47-54.	0.9	52
440	Clinical trials and novel pathogens: lessons learned from SARS. Emerging Infectious Diseases, 2004, 10, 389-94.	2.0	15
441	Resistance to antibiotics: administrative response to the challenge. Managed Care Interface, 2004, 17, 20-9.	0.2	5
442	Clinical manifestations associated with the aberrant expression of the soluble granulocyte-macrophage colony-stimulating factor receptor in patients presenting with haematological malignancies. British Journal of Haematology, 2003, 121, 86-93.	1.2	2
443	Is resistance futile?. Nature Medicine, 2003, 9, 390-392.	15.2	22
444	Use of, Effectiveness of, and Attitudes Regarding Influenza Vaccine Among House Staff. Infection Control and Hospital Epidemiology, 2003, 24, 839-844.	1.0	136
445	Association of Human Leukocyte Antigen with Outcomes of Infectious Diseases: The Streptococcal Experience. Scandinavian Journal of Infectious Diseases, 2003, 35, 665-669.	1.5	36
446	High Heart Rates at Anaerobic Threshold in Healthy Women. Archives of Internal Medicine, 2003, 163, 2101.	4.3	0
447	Emergence of Macrolide Resistance in Throat Culture Isolates of Group A Streptococci in Ontario, Canada, in 2001. Antimicrobial Agents and Chemotherapy, 2003, 47, 2370-2372.	1.4	47
448	Risk Factors for Resistance to Antimicrobial Agents among Nursing Home Residents. American Journal of Epidemiology, 2003, 157, 40-47.	1.6	121
449	Identification of Severe Acute Respiratory Syndrome in Canada. New England Journal of Medicine, 2003, 348, 1995-2005.	13.9	1,009
450	SARS â€" One Year Later. New England Journal of Medicine, 2003, 349, 2381-2382.	13.9	40

#	Article	IF	CITATIONS
451	Clinical and Epidemiologic Features of Group A Streptococcal Pneumonia in Ontario, Canada. Archives of Internal Medicine, 2003, 163, 467.	4.3	69
452	Antimicrobial Susceptibility Breakpoints and First-Step <i>parC</i> Mutations in <i>Streptococcus pneumoniae</i> : Redefining Fluoroquinolone Resistance. Emerging Infectious Diseases, 2003, 9, 833-837.	2.0	93
453	Invasive Group A Streptococcal Disease: Risk Factors for Adults. Emerging Infectious Diseases, 2003, 9, 970-977.	2.0	117
454	Investigation of a nosocomial outbreak of severe acute respiratory syndrome (SARS) in Toronto, Canada. Cmaj, 2003, 169, 285-92.	0.9	195
455	Laboratory Contamination of Specimens with Quality Control Strains of Vancomycin-Resistant Enterococci in Ontario. Journal of Clinical Microbiology, 2002, 40, 2686-2688.	1.8	9
456	An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections. Nature Medicine, 2002, 8, 1398-1404.	15.2	339
457	Laboratory Characterization of Methicillinâ€ResistantStaphylococcus aureusin Canadian Hospitals: Results of 5 Years of National Surveillance, 1995–1999. Journal of Infectious Diseases, 2002, 186, 652-660.	1.9	91
458	Prevention of Invasive Group A Streptococcal Disease among Household Contacts of Case Patients and among Postpartum and Postsurgical Patients: Recommendations from the Centers for Disease Control and Prevention. Clinical Infectious Diseases, 2002, 35, 950-959.	2.9	142
459	Severe Group A Streptococcal Soft-Tissue Infections in Ontario: 1992–1996. Clinical Infectious Diseases, 2002, 34, 454-460.	2.9	136
460	Activities of New Fluoroquinolones, Ketolides, and Other Antimicrobials against Blood Culture Isolates of Viridans Group Streptococci from across Canada, 2000. Antimicrobial Agents and Chemotherapy, 2002, 46, 1553-1556.	1.4	26
461	Annualized Incidence and Spectrum of Illness from an Outbreak Investigation of Bell's Palsy. Neuroepidemiology, 2002, 21, 255-261.	1.1	84
462	Activity of BMS-284756, a Novel Des-Fluoro(6) Quinolone, against Staphylococcus aureus, Including Contributions of Mutations to Quinolone Resistance. Antimicrobial Agents and Chemotherapy, 2002, 46, 1119-1121.	1.4	17
463	Clinical aspects and cost of invasive Streptococcus pneumoniae infections in children: resistant vs. susceptible strains. International Journal of Antimicrobial Agents, 2002, 20, 113-118.	1.1	20
464	Exploring the Pathogenesis of Necrotizing Fasciitis Due to Streptococcus pneumoniae. Scandinavian Journal of Infectious Diseases, 2002, 34, 639-644.	1.5	14
465	Microbiologic findings and risk factors for antimicrobial resistance at myringotomy for tympanostomy tube placementâ€"a prospective study of 601 children in Toronto. International Journal of Pediatric Otorhinolaryngology, 2002, 66, 227-242.	0.4	18
466	Prospective Surveillance for Primary Bloodstream Infections Occurring in Canadian Hemodialysis Units. Infection Control and Hospital Epidemiology, 2002, 23, 716-720.	1.0	112
467	Antimicrobial Resistance among Clinical Isolates of Streptococcus pneumoniae in Canada during 2000. Antimicrobial Agents and Chemotherapy, 2002, 46, 1295-1301.	1.4	86
468	Quality and methods of developing practice guidelines. BMC Health Services Research, 2002, 2, 1.	0.9	63

#	Article	IF	CITATIONS
469	Optimizing antibiotics in residents of nursing homes: protocol of a randomized trial. BMC Health Services Research, 2002, 2, 17.	0.9	33
470	Use of Oseltamivir During Influenza Outbreaks in Ontario Nursing Homes, 1999–2000. Journal of the American Geriatrics Society, 2002, 50, 608-616.	1.3	121
471	An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections. Nature Medicine, 2002, 8, 1398-1404.	15.2	167
472	Oseltamivir was safe and effective for prophylaxis of influenza in the frail elderly. ACP Journal Club, 2002, 136, 24.	0.1	0
473	Zanamivir use during transmission of amantadine-resistant influenza A in a nursing home. International Congress Series, 2001, 1219, 823-828.	0.2	1
474	Molecular mechanisms of cefoxitin resistance in Escherichia coli from the Toronto area hospitals. Diagnostic Microbiology and Infectious Disease, 2001, 41, 57-63.	0.8	35
475	Development of Minimum Criteria for the Initiation of Antibiotics in Residents of Long-Term–Care Facilities: Results of a Consensus Conference. Infection Control and Hospital Epidemiology, 2001, 22, 120-124.	1.0	352
476	A Blinded Comparison of Three Laboratory Protocols for the Identification of Patients Colonized With Methicillin-Resistant Staphylococcus aureus. Infection Control and Hospital Epidemiology, 2001, 22, 152-156.	1.0	32
477	A RANDOMIZED TRIAL TO MEASURE THE OPTIMAL ROLE OF THE PHARMACIST IN PROMOTING EVIDENCE-BASED ANTIBIOTIC USE IN ACUTE CARE HOSPITALS. International Journal of Technology Assessment in Health Care, 2001, 17, 171-180.	0.2	29
478	Population-based active surveillance for neonatal group B streptococcal infections in Alberta, Canada: implications for vaccine formulation. Pediatric Infectious Disease Journal, 2001, 20, 879-884.	1.1	102
479	Identifying research priorities on infections in older adults: proceedings of an interdisciplinary workshop. BMC Geriatrics, $2001, 1, 1$.	1.1	6
480	Antibiotic use in ontario facilities that provide chronic care. Journal of General Internal Medicine, 2001, 16, 376-383.	1.3	147
481	A 2 factor model helped to rule out early stage necrotising fasciitis. Evidence-Based Medicine, 2001, 6, 96-96.	0.6	0
482	Antibodies to Capsular Polysaccharides of Group BStreptococcusin Pregnant Canadian Women: Relationship to Colonization Status and Infection in the Neonate. Journal of Infectious Diseases, 2001, 184, 285-291.	1.9	101
483	Oropharyngeal Candidiasis in Patients with Human Immunodeficiency Virus: Correlation of Clinical Outcome with In Vitro Resistance, Serum Azole Levels, and Immunosuppression. Clinical Infectious Diseases, 2001, 32, 1554-1561.	2.9	23
484	Evaluation of Susceptibility Testing To Detect Fluoroquinolone Resistance Mechanisms in Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy, 2001, 45, 1911-1914.	1.4	38
485	Prevalence and Mechanisms of Macrolide Resistance in Invasive and Noninvasive Group B Streptococcus Isolates from Ontario, Canada. Antimicrobial Agents and Chemotherapy, 2001, 45, 3504-3508.	1.4	144
486	A Nosocomial Outbreak of Fluoroquinoloneâ€ResistantStreptococcus pneumoniae. Clinical Infectious Diseases, 2001, 33, 517-522.	2.9	114

#	Article	IF	Citations
487	Evidence for Superantigen Involvement in Severe Group A Streptococcal Tissue Infections. Journal of Infectious Diseases, 2001, 184, 853-860.	1.9	112
488	Intravenous Itraconazole Followed by Oral Itraconazole in the Treatment of Invasive Pulmonary Aspergillosis in Patients with Hematologic Malignancies, Chronic Granulomatous Disease, or AIDS. Clinical Infectious Diseases, 2001, 33, e83-e90.	2.9	145
489	A 2-factor model helped rule out early-stage necrotizing fasciitis. ACP Journal Club, 2001, 134, 117.	0.1	O
490	Host variation in cytokine responses to superantigens determine the severity of invasive group A streptococcal infection. European Journal of Immunology, 2000, 30, 3247-3255.	1.6	115
491	Use of Antiviral Prophylaxis in Influenza Outbreaks in Long Term Care Facilities. Canadian Journal of Infectious Diseases & Medical Microbiology, 2000, 11, 187-192.	0.3	7
492	Genetic Relatedness and Superantigen Expression in Group A Streptococcus Serotype M1 Isolates from Patients with Severe and Nonsevere Invasive Diseases. Infection and Immunity, 2000, 68, 3523-3534.	1.0	252
493	Cigarette Smoking and Invasive Pneumococcal Disease. New England Journal of Medicine, 2000, 342, 681-689.	13.9	697
494	Inverse Relation between Disease Severity and Expression of the Streptococcal Cysteine Protease, SpeB, among Clonal M1T1 Isolates Recovered from Invasive Group A Streptococcal Infection Cases. Infection and Immunity, 2000, 68, 6362-6369.	1.0	150
495	Zanamivir Use During Transmission of Amantadine-Resistant Influenza A in a Nursing Home. Infection Control and Hospital Epidemiology, 2000, 21, 700-704.	1.0	55
496	The Nature and Frequency of Blood Contacts Among Home Healthcare Workers. Infection Control and Hospital Epidemiology, 2000, 21, 765-770.	1.0	34
497	Etiology of community-acquired pediatric viral diarrhea: a prospective longitudinal study in hospitals, emergency departments, pediatric practices and child care centers during the winter rotavirus outbreak, 1997 to 1998. Pediatric Infectious Disease Journal, 2000, 19, 843-848.	1.1	79
498	Inverse Relation between Disease Severity and Expression of the Streptococcal Cysteine Protease, SpeB, among Clonal M1T1 Isolates Recovered from Invasive Group A Streptococcal Infection Cases. Infection and Immunity, 2000, 68, 6362-6369.	1.0	15
499	Evaluation of <scp>d</scp> -Xylose and 1% Methyl-α- <scp>d</scp> -Glucopyranoside Fermentation Tests for Distinguishing <i>Enterococcus gallinarum</i> from <i>Enterococcus faecium</i> Journal of Clinical Microbiology, 2000, 38, 3652-3655.	1.8	14
500	The Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study of neonatal group B streptococcal infections in Canada. Paediatrics and Child Health, 1999, 4, 257-263.	0.3	20
501	A Cross-Canada Survey of Cytomegalovirus Prevention and Treatment Practices in Bone Marrow Transplant Recipients. Canadian Journal of Infectious Diseases & Medical Microbiology, 1999, 10, 410-414.	0.3	1
502	Risk Factors in the Pathogenesis of Invasive Group A Streptococcal Infections: Role of Protective Humoral Immunity. Infection and Immunity, 1999, 67, 1871-1877.	1.0	127
503	Elevated Serum Cytokines Are Associated with Cytomegalovirus Infection and Disease in Bone Marrow Transplant Recipients. Journal of Infectious Diseases, 1999, 179, 484-488.	1.9	84
504	Intravenous Immunoglobulin Therapy for Streptococcal Toxic Shock Syndromeâ€"A Comparative Observational Study. Clinical Infectious Diseases, 1999, 28, 800-807.	2.9	513

#	Article	IF	Citations
505	Molecular Characterization of a Nosocomial Outbreak of Human Respiratory Syncytial Virus on an Adult Leukemia/Lymphoma Ward. Journal of Infectious Diseases, 1999, 180, 1686-1689.	1.9	63
506	Rapid selection of complement-inhibiting protein variants in group A Streptococcus epidemic waves. Nature Medicine, 1999, 5, 924-929.	15.2	107
507	The clinical utility of CMV surveillance cultures and antigenemia following bone marrow transplantation. Bone Marrow Transplantation, 1999, 23, 45-51.	1.3	14
508	Practical approach to the identification of clinically relevant Enterococcus species. Diagnostic Microbiology and Infectious Disease, 1999, 34, 165-171.	0.8	47
509	Two-year survey of Alberta laboratories processing of antenatal group B streptococcal (GBS) screening specimens: implications for GBS screening programs. Diagnostic Microbiology and Infectious Disease, 1999, 35, 169-176.	0.8	19
510	A Comparison of Model-Building Strategies for Lower Respiratory Tract Infection in Long-Term Care. Journal of Clinical Epidemiology, 1999, 52, 1239-1248.	2.4	7
511	Control of Transmission of Vancomycin-Resistant Enterococcus faecium in a Long-Term–Care Facility. Infection Control and Hospital Epidemiology, 1999, 20, 312-317.	1.0	66
512	Decreased Susceptibility of Streptococcus pneumoniaeto Fluoroquinolones in Canada. New England Journal of Medicine, 1999, 341, 233-239.	13.9	995
513	Prospective Evaluation of Risk Factors for Bloodstream Infection in Patients Receiving Home Infusion Therapy. Annals of Internal Medicine, 1999, 131, 340.	2.0	124
514	Risk Factors for Pneumonia and Other Lower Respiratory Tract Infections in Elderly Residents of Long-term Care Facilities. Archives of Internal Medicine, 1999, 159, 2058.	4.3	298
515	Two Nursing Home Outbreaks of Respiratory Infection with <i>Legionella sainthelensi</i> the American Geriatrics Society, 1999, 47, 547-552.	1.3	41
516	Influenza Vaccination in Long-Term–Care Facilities: Structuring Programs for Success. Infection Control and Hospital Epidemiology, 1999, 20, 499-503.	1.0	33
517	Clinical Experience with 20 Cases of Group A Streptococcus Necrotizing Fasciitis and Myonecrosis: 1995 to 1997. Plastic and Reconstructive Surgery, 1999, 103, 1567-1573.	0.7	43
518	Clinical Experience with 20 Cases of Group A Streptococcus Necrotizing Fasciitis and Myonecrosis: 1995 to 1997. Plastic and Reconstructive Surgery, 1999, 103, 1567-1573.	0.7	87
519	CLINICAL UTILITY OF QUANTITATIVE CYTOMEGALOVIRUS VIRAL LOAD DETERMINATION FOR PREDICTING CYTOMEGALOVIRUS DISEASE IN LIVER TRANSPLANT RECIPIENTS1. Transplantation, 1999, 68, 1305-1311.	0.5	202
520	Risk Factors in the Pathogenesis of Invasive Group A Streptococcal Infections: Role of Protective Humoral Immunity. Infection and Immunity, 1999, 67, 1871-1877.	1.0	20
521	The rapid emergence of a new strain of MRSA in Ontario: Laboratory implications. Antimicrobics and Infectious Diseases Newsletter, 1998, 17, 27-29.	0.0	0
522	Varying Titers of Neutralizing Antibodies to Streptococcal Superantigens in Different Preparations of Normal Polyspecific Immunoglobulin G: Implications for Therapeutic Efficacy. Clinical Infectious Diseases, 1998, 26, 631-638.	2.9	93

#	Article	IF	Citations
523	Effect of Cytomegalovirus Infection on 1‥ear Mortality Rates Among Recipients of Allogeneic Bone Marrow Transplants. Clinical Infectious Diseases, 1998, 26, 606-610.	2.9	17
524	Skin and soft tissue infection. Current Opinion in Infectious Diseases, 1998, 11, 119-124.	1.3	25
525	The use of Streptococcus pneumoniae nasopharyngeal isolates from healthy children to predict features of invasive disease. Pediatric Infectious Disease Journal, 1998, 17, 279-286.	1.1	89
526	Opsonic Antibodies to the Surface M Protein of Group A Streptococci in Pooled Normal Immunoglobulins (IVIG): Potential Impact on the Clinical Efficacy of IVIG Therapy for Severe Invasive Group A Streptococcal Infections. Infection and Immunity, 1998, 66, 2279-2283.	1.0	51
527	Diagnosis of Group A Streptococcal Necrotizing Fasciitis by Using PCR To Amplify the Streptococcal Pyrogenic Exotoxin B Gene. Journal of Clinical Microbiology, 1998, 36, 1769-1771.	1.8	36
528	Can pregnant women obtain their own specimens for group B streptococcus? A comparison of maternal versus physician screening. The Mount Sinai GBS Screening Group. Family Practice, 1997, 14, 403-406.	0.8	20
529	Population-Based Surveillance for Group A Streptococcal Necrotizing Fasciitis: Clinical Features, Prognostic Indicators, and Microbiologic Analysis of Seventy-Seven Cases. American Journal of Medicine, 1997, 103, 18-24.	0.6	474
530	Invasive Infections Due to a Fish Pathogen, Streptococcus iniae. New England Journal of Medicine, 1997, 337, 589-594.	13.9	298
531	Novel Superantigens from Streptococcal Toxic Shock Syndrome Streptococcus pyogenes Isolates. Advances in Experimental Medicine and Biology, 1997, 418, 525-529.	0.8	5
532	Invasive Group A Streptococcal Infections in Ontario, Canada. New England Journal of Medicine, 1996, 335, 547-554.	13.9	678
533	Influenza and Pneumococcal Vaccination and Tuberculin Skin Testing Programs in Long-Term Care Facilities: Where Do We Stand?. Infection Control and Hospital Epidemiology, 1995, 16, 18-24.	1.0	18
534	Tuberculosis Surveillance Practices in Long-Term Care Institutions. Infection Control and Hospital Epidemiology, 1995, 16, 148-151.	1.0	9
535	Gadolinium-based MR contrast media: potential for growth of microbial contaminants when single vials are used for multiple patients American Journal of Roentgenology, 1995, 165, 669-671.	1.0	16
536	Selective Depletion Of VÂ-Bearing T Cells In Patients With Severe Invasive Group A Streptococcal Infections And Streptococcal Toxic Shock Syndrome. Journal of Infectious Diseases, 1995, 171, 74-84.	1.9	115
537	Evaluation of Short-Course Therapy with Cefixime or Rifampin for Eradication of Pharyngeally Carried Group A Streptococci. Clinical Infectious Diseases, 1995, 21, 1294-1296.	2.9	22
538	HIV-Associated Lymphoma of the Gastrointestinal Tract: The University of Toronto AIDS-Lymphoma Study Group Experience. Leukemia and Lymphoma, 1995, 16, 343-349.	0.6	12
539	In vitro activities of antimicrobial combinations against Stenotrophomonas (Xanthomonas) maltophilia. Antimicrobial Agents and Chemotherapy, 1995, 39, 2220-2223.	1.4	65
540	Pharmacoeconomic Analysis of Empirical Therapy with Ceftazidime Alone or Combination Antibiotics for Febrile Neutropenia in Cancer Patients. Pharmacoeconomics, 1995, 7, 49-62.	1.7	21

#	Article	IF	Citations
541	Influenza and Pneumococcal Vaccination and Tuberculin Skin Testing Programs in Long-Term Care Facilities: Where Do We Stand?. Infection Control and Hospital Epidemiology, 1995, 16, 18-24.	1.0	12
542	Tuberculosis Surveillance Practices in Long-Term Care Institutions. Infection Control and Hospital Epidemiology, 1995, 16, 148-151.	1.0	9
543	Determination of antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae and characterization of their beta-lactamases. Canadian Haemophilus Study Group. Antimicrobial Agents and Chemotherapy, 1994, 38, 1678-1680.	1.4	107
544	Diagnosis of Whipple's Disease by Molecular Analysis of Peripheral Blood. New England Journal of Medicine, 1994, 331, 1343-1346.	13.9	77
545	The Use of Molecular Typing Techniques in the Epidemiologic Investigation of Resistant Enterococci. Infection Control and Hospital Epidemiology, 1994, 15, 548-556.	1.0	15
546	Surveillance of susceptibility testing methodologies for Haemophilus influenzae in Canada, including evaluation of disk diffusion test. Journal of Clinical Microbiology, 1994, 32, 2013-2015.	1.8	11
547	Recent advances in the management of infections in cancer patients. Critical Reviews in Oncology/Hematology, 1993, 15, 175-190.	2.0	2
548	Request for reports on experiences with definitions of infection for surveillance in long-term care. American Journal of Infection Control, 1993, 21, 333.	1.1	0
549	Evidence for a clonal origin of methicillin resistance in Staphylococcus aureus. Science, 1993, 259, 227-230.	6.0	423
550	A Cluster of Surgical Wound Infections Due to Unrelated Strains of Group a Streptococci. Infection Control and Hospital Epidemiology, 1993, 14, 265-267.	1.0	4
551	Utilization review of the use of BACTEC PLUS high-volume blood culture bottles. Journal of Clinical Microbiology, 1993, 31, 2794-2795.	1.8	5
552	Incorporating variations in the quality of individual randomized trials into meta-analysis. Journal of Clinical Epidemiology, 1992, 45, 255-265.	2.4	579
553	Pseudoepidemic of Nocardia asteroides associated with a mycobacterial culture system. Journal of Clinical Microbiology, 1992, 30, 1357-1360.	1.8	23
554	Broth microdilution testing of Haemophilus influenzae with haemophilus test medium versus lysed horse blood broth. Canadian Haemophilus Study Group. Journal of Clinical Microbiology, 1992, 30, 2284-2289.	1.8	18
555	Definitions of infections. American Journal of Infection Control, 1991, 19, 171.	1.1	2
556	Definitions of infection for surveillance in long-term care facilities. American Journal of Infection Control, 1991, 19, 1-7.	1.1	430
557	Effect of an Automated Sink on Handwashing Practices and Attitudes in High-Risk Units. Infection Control and Hospital Epidemiology, 1991, 12, 422-428.	1.0	76
558	Effect of an Automated Sink on Handwashing Practices and Attitudes in High-Risk Units. Infection Control and Hospital Epidemiology, 1991, 12, 422-428.	1.0	53

#	Article	IF	CITATIONS
559	Epidemiology of Needlestick Injuries in House Officers. Journal of Infectious Diseases, 1990, 162, 961-964.	1.9	91
560	Surveillance for Quality Assessment: II. Surveillance for Noninfectious Processes: Back to Basics. Infection Control and Hospital Epidemiology, 1990, 11, 36-41.	1.0	5
561	Use of molecular typing to study the epidemiology of Serratia marcescens. Journal of Clinical Microbiology, 1990, 28, 55-58.	1.8	42
562	Activities of daptomycin and teicoplanin against Staphylococcus haemolyticus and Staphylococcus epidermidis, including evaluation of susceptibility testing recommendations. Antimicrobial Agents and Chemotherapy, 1989, 33, 585-588.	1.4	30
563	The buffering capacity of the internal phase of thylakoids and the magnitude of the pH changes inside under flashing light. Biochimica Et Biophysica Acta - Bioenergetics, 1979, 546, 121-141.	0.5	157
564	Terminal Cross-linking of DNA Catalyzed by an Enzyme System Containing DNA Ligase, DNA Polymerase, and Exonuclease of Bacteriophage T7. Canadian Journal of Biochemistry, 1974, 52, 525-535.	1.4	20
565	The Reemergence of Severe Group A Streptococcal Disease: an Evolutionary Perspective. , 0, , 93-123.		20
566	Similar Duration of Viral Shedding of the Delta Variant of SARS-CoV-2 Between Vaccinated and Incompletely Vaccinated Individuals. Infection Control and Hospital Epidemiology, 0, , 1-13.	1.0	7